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ABSTRACT
Although amyloid β (Aβ) deposition has been a hallmark of Alzheimer’s disease (AD),
the physiological function of amyloid precursor protein (APP) is not clear. Our results
suggested that high concentration of APP induces glial differentiation while
physiological level of APP promotes migration and differentiation of neural stem cell
(HNSC). HNSCs were mainly differentiated into astrocytes when they are transplanted
into APP transgenic mouse brain or treated with a high concentration of secreted-type
APP (sAPP) in culture.

Staurosporine (STS) induced a distinctive astrocytic morphology in NT-2/D1 neural
progenitor cells with expressions of APP and astrocyte-specific markers, glial fibrillary
acidic protein (GFAP), aspartate transporter, and glutamate transporter-1. Expression of
APP is correlated with GFAP expression in both mRNA and protein level in this
experiment. Inhibition of APP expression by RNA interference (RNAi) or treatment with
MEK1 inhibitor (PD098059), which reduces APP expression by suppressing ERK
phosphorylation, abolished GFAP expression. These results indicate that STS induces
glial differentiation of neuronal progenitor cells by increasing APP levels through
activation of ERK pathway.

We also found that APP-induced glial differentiation of neural progenitor NT-2/D1 cells
is mediated by activation of IL-6/gp130 and notch signaling pathway. Treatment of APP
activated IL-6/gp130 signal pathway via protein-protein interaction between APP and
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gp130 and it increased the gene expressions of CNTF, gp130 and JAK1, and
phosphorylation of STAT3 while gene silencing of CNTF, JAK1 or STAT3 by RNAi, or
treatment the cells with antibodies recognizing gp130 suppressed GFAP expression,
indicating these molecules are crucial for APP-induced glial differentiation. Thus
treatment of sAPP may promote glial differentiation of neural progenitor cells by
activation of IL-6/gp130 signaling cascade.

Treatment of sAPP increased the generation of notch intracellular domain as well as
gene expression of Hes1 but did not change expression levels of notch or its ligands.
We also found protein-protein interaction of APP and notch using immunoprecipitation
suggesting that glial differentiation of NT-2/D1 cells is mediated by the physical
interaction between APP and notch. N-terminal domain of APP (1-205 a.a.) alone can
bind to notch and activate these signaling cascade in NT-2/D1 cells. Thus, APP may
induce glial differentiation through activation of IL-6/gp130 and notch signal cascade by
binding with its N-terminal domain. Taken together, our results suggest that APP
regulates neural stem cell (NSC) differentiation through IL-6/gp130 and notch signaling
pathway. Furthermore, the activation of both glial differentiation mechanisms may be
necessary to potentiate APP-induced glial differentiation of NSC.

Altered APP metabolism in Down syndrome and Alzheimer’s disease may accelerate
premature glial differentiation of NSCs, resulting in gliosis found in these diseases.
Although it is not clear that how adult neurogenesis contributes to maintain normal brain
function, destruction of neuroreplacement mechanism by NSCs may pose a problem.
iv

We may also have to consider effect of APP on the stem cell therapy for these diseases,
since HNSCs may not properly differentiate into neurons under these pathological
conditions.
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GENERAL INTRODUCTION

General background of Alzheimer’s diseases
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases,
resulting in a progressive, irreversible brain disorder such as dementia. It attacks and
slowly destroys the mind of the afflicted person. More than 4.5 million Americans are
believed to have AD and by 2050, the number could increase to 14 million.
Approximately 59,000 victims die and 350,000 new cases of AD are diagnosed each
year 1. In general, pathology of AD is caused by the deposition of amyloid plaque and
the appearance of the neurofibrillary tangles. The major symptoms of the disease
include memory loss, confusion, impaired judgment, personality changes, disorientation,
and loss of language skills 2.

Genetic studies have showed that missense mutations in the APP and presenilins 1/2 ,
encoded on chromosome 21, 14, and 1, respectively, cause early-onset familiar AD
(FAD) 3-5. Mutations of those genes enhance AD by upregulating the proteolytic process
of APP, resulting in increase of Aβ peptide generation as well as extracellular senile
plaque deposition. In the case of the late-onset of AD, variants of apolipoprotein E
(APOE) gene are a highly suspected factor6. While APOE ε4 allele is closely associated
with APP processing by modulating cholesterol level in the brain 7, APOE ε3 allele
modulates tau metabolism by interacting with tau 8.

1

Biology of APP and Aβ
APP is a type 1 single transmembrane protein, consisting of 695-770 amino acids. The
APP gene is approximately 240 Kb, located on chromosome 21, and harbors 19 exons 9.
Depends on alternative splicing of exon 7, 8, and 15, several different type of splice
variants (APP695, APP751, and APP770) are generated in the cells with tissue
specifically and each splice variants have distinctive characteristics. For example,
APP770, containing exon 7, has a function in blood clotting since it contains Kunitz-type
proteinase inhibitor (KPI) domain 10. However, APP695, lacking KPI domain, is
specifically expressed in neuron 11, 12.

The APP family consists of APP, APLP1, APLP2 13-15, APL-1 in C.elegans 16, and APPL
in Drosophila 17. These APP molecules harbor several consensus motifs such as E1
and E2 and show higher sequence homology as well. Therefore, APP families share
functional similarity and show functional redundancy in in-vivo Alzheimer’s studies.

Due to the cytotoxicity of Aβ peptides in the brain, mechanism of the proteolytic
processing of APP has been intensively studied to understand the pathophysiology of
AD. Generation of Aβ peptides result from various combination of the cleavage by β-,
and γ-secretases. The major proteolytic cleavage of APP is performed by α-secretase
(ex, ADAM10) 18, cleaves between residues Lys612 and Leu613 of APP, whereas βsecretase (ex, BACE1) cleaves APP after Met596 and Tyr606 19-21. Cleavage of α- and
β-secretase produces soluble APPs (sAPPα and sAPPβ) as well as α- and β- carboxyl
terminal of APP fragments (CTFs) of APP. Then, γ-secretase cleaves C-terminal of APP
2

to liberate either amyloidogenic Aβ peptides or p3 in combination with BACE1 or
ADAM10, respectively 22. Furthermore, APP intracellular domain, functioning
phosphoinositide-medidated calcium signaling 23, apoptosis 24, and transcription
regulation 25, is generated by γ-secretase activity. Therefore, β- and γ-secretase has a
critical role in Aβ generation and senile plaque deposition in AD (Figure 1.).

3

EC

Aβ

IC

TM

NH2

COOH

α-secretase

β α

APP

β-secretase

APPα

APPβ

NH2

NH2

APP-CTFβ

APP-CTFα
COOH

γ

COOH

γ
γ-secretase

γ-secretase
Aβ

P3
COOH

AICD

AICD

Figure 1: Schematic diagram of sequential processing of APP by α-, β-, γ-secretases.
EC: extracellular, IC: intracellular, TM: transmembrane. Aβ domain is highlighted in
blue.
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Structural and functional properties of APP
Despite the wealth of studies regarding the physiological function(s) of APP, there is
little consensus between its function in vitro and in vivo. The main reason that
physiological function(s) of APP is (are) still under debates is caused by the molecular
complexity of APP. Due to its molecular complexity, various functions have been
attributed in the same domain of APP in the CNS. Therefore, to investigate the
physiological function of APP, the structural property of APP should be well understood.
In general, functional domain of APP can be classified with E1 domain, central APP
domain (CAPPD), E2 domain, and APP intracellular domain (AICD) 26.

E1 domain harbors growth-factor like domain (GFLD) (23-128 a.a) which has been
know to have cysteine rich region and heparin binding site27. Since it contains highly
positively charged surface, GFLD functions like a growth factor through protein-protein
interaction with other counterpart molecules. Current studies have showed that GFLD is
associated with cell adhesion, which contributes to neurite outgrowth and
synaptogenesis28. Then, E1 domain is followed by the well-studied E2 domain. E2
domain contains RERMS sequence29 and heparin-sulfate proteoglycan binding site30,
function as a growth promoting factor. AICDs are generated by subsequent cleavage of
APP by γ-secretase/nicastrin complex. Since this domain has several important
structural properties, AICD has been extensively studied and found that it is associated
with multiple signaling pathways23. The structural properties of the cytoplasmic region of
APP suggest that APP might have a role as a G-protein coupled receptor, via Go
binding domain in AICD31. Above all, AICDs modulate signaling pathway by interacting
5

with various partners, including Fe65, JIP, X11/Mint, and mDab1, via YENPTY motif32
(Figure 2.).

Plasma membrane

KPI (Exon7)

NH2

GFLD

CuBD

-------------- E1-----------

RERMS

CAPPD

-------------- E2 ----------- - Aβ Extracullular

COOH

AICD

Intracellular

Figure 2: Schematic diagram of domain organization of APP. E1 domain is composed
with N-terminal growth factor like domain (GFLD) and copper-binding domain (CuBD).
E1 is followed by E2/central APP domain (CAPPD) which is, so called, carbohydrate
domain. Aβ indicates that Aβ domain. In APP751 and APP770, KPI domain is included
by alternative splicing.
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Glial differentiation of neural stem cells
During vertebrate central nervous system (CNS) development, progenitor cells are,
specifically subdivided into certain location. After being settled down to specific region,
those progenitors start to proliferate to increase the number of the cells during postgastrulation stage (expansion phase) and then are differentiated into neuron
(neurogenic phase) and glia (gliogenic phase) during mid-gestation and postnatal stage,
respectively33. Accumulated evidences suggest that neurons are typically differentiated
before astrocytes and oligodendrocytes with the exception of a few sites where
postnatal and adult neurogenesis occur during later development, such as the
subventricular zone (SVZ) of the fore brain. Recent studies show that these timing of
the sequential differentiation events are finely modulated by both intrinsic and extrinsic
cues.

During neurogenic phase (around E12-13), several morphogens induce neuronal
differentiation with selective or instructive manner. Platelet-derived growth factor
(PDGF) 34 and vascular endothelial growth factor (VEGF) 35 is involved in the promotion
of neuronal differentiation by selectively enhancing neuronal population. Inversely, Wnt
signaling pathway is also implicated with instructive neuronal differentiation by
upregulating Neurogenin 1, 2 (Ngn1, 2), proneural basic helix-loop-helix transcription
factors. Additionally, Wnt signaling pathway has a potent suppressive role on FGF2,
one of the gliogenic factors 36-38.
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In the later stage of the neural differentiation (around postnatal period), glial
differentiation is induced by various factors. To date, IL-6 cytokine families, bone
morphogenic factors (BMPs), basic fibroblast growth factor (bFGF), and Notch signaling
has been known for an important mechanism which is involved in the glial differentiation
process 39.

IL-6-induced JAK/STAT signaling pathway is a central part of the glial differentiation
process 40 (Figure 3). This gliogenic signaling pathway is stimulated by several IL-6
family cytokines such as leukemia inhibitory factor (LIF) 41, ciliary neurotrophic factor
(CNTF) 42, IL-6, and oncostatin M (OSM) 43. Once these IL-6 cytokine families interact
with their cognate receptors (ex, IL-6 receptor α), the resultant complexes are then
associated with gp130, crucial signal transducing component of IL-6 receptor44.
Formation of these receptor heterodimers stimulates a downstream transcription factor,
signal transducer and activator of transcription (STAT) proteins by activation of JAKs,
especially JAK1 and JAK2. Predominantly, STAT3 molecules get phosphorylation, and
then the phosphorylated STAT3s form dimerization and undergo translocation into the
nucleus. Finally, STAT3 dimers bind to the putative STAT3 binding element of GFAP
promoter, typical astrocytic marker, for glial differentiation45.

Notch signaling has been known to control cell fate through local cell-cell interaction.
During development process, Notch suppresses neuronal differentiation in many
organisms in vivo and in vitro (Figure 3). When ligands (ex., Delta and Jagged) bind to
Notch, it results in proteolytic cleavage of Notch receptors by γ-secretase/nicastrin
8

complex to release the signal-transducing Notch intracellular domain (NICD). Generated
NICDs translocate into nucleus and interact with the nuclear protein which is referred to
as CBF1/Su(H)/Lag-1 (CSL) 46. Complex of CSL and NICD activates expression of
primary target genes of Notch such as Hairy and enhancer of split (Hes) gene families.
Then, Hes, a basic helix-loop-helix (bHLH) type transcriptional repressor, suppresses
expression of the proneural transcription factors such as Mash1 and NeuroD47, 48.

Interesting feature of glial differentiation is that signaling mechanisms, associated with
glial differentiation, are strengthened by cross-talking. Glial differentiation is enhanced
by cross-talking between IL-6 and Notch signaling pathways by interacting with Hes1
and JAK2. When Notch target gene, Hes1, expression is upregulated, it physically
interact with JAK2. Then, these complexes interact with STAT3 and enhance
accessibility of STAT3 molecule to STAT3 binding element of GFAP promoter 49.

Although BMPs have multiple functions in the neural differentiation, it is also associated
with glial differentiation during late gestation or postnatal stage50. During differentiation
process, Smad1, stimulated by BMPs, makes a complex with transcription coactivator,
CBP/P300, and STAT3 molecules. Then, those complexes have higher accessibility to
STAT3 binding element of GFAP promoter51. Therefore, overall glial differentiation
process is promoted by cross-talking between these gliogenic signaling pathways.

Though some of these gliogenic factors are expressed throughout the neural
differentiation process, they show different effect to the neural progenitor cells along
9

with the developmental stage. This stage specificity is modulated by the intrinsic factor
such as methylation status. Depends on the methylation status of CpG island within the
STAT3 binding element of STAT3 promoter and histone H3, it determines the stage
specificity of gliogenic factors. If STAT3 promoter is methylated and histone H3 is
demethylated, it may not be able to induce glial differentiation of neural stem cells since
STAT3 complexes are not be able to access to GFAP promoter52, 53.

10

Figure 3: Schematic diagram of two representative glial differentiation mechanisms.
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Rationale and aims
Although APP is one of the most intensively studied molecules because of it importance
in pathology of AD, the physiological function of APP is still controversial and needs to
be elucidated. However, several structural properties of APP have been revealed as a
growth factor or a ligand. Crystal structure of the cystein-rich, heparin-binding Nterminal domain of APP reveals a growth-factor like domain configuration 27. Moreover,
several lines of reports have introduced the novel function of APP as a ligand which
interacts with various receptors, such as the class A scavenger receptor (SR-A) 54 and
LDL receptor related protein (LRP) receptor 55. These studies indicate that secreted
type of soluble APP may modulate cellular function such as differentiation via certain
receptors, similar with extrinsic factors in glial differentiation. On the other hand, since
DS is a trisomy of chromosome 21, contains the APP gene, DS patients have extra
copies of the APP gene in their genetic makeup. Therefore, DS patients usually show
high level expression of APP and similar symptoms on their later onset. Bhan et al.
reported that most of Down’s syndrome (DS) patient’s neural stem cells were mainly
differentiated into astrocytes 56. Due to the functional property of N-terminal domain of
APP, overexpressed APP affects cell fate specification of neural stem cells in DS
patients.

As mentioned above, although several gliogenic factors have been reported up to now,
there remains the possibility of other factors that might induce glial differentiation by
unknown mechanism. Thus, here, we proposed that sAPP may be a novel extrinsic
factor which is necessary for the glial differentiation of neural progenitor cells. The main
12

purpose of the studies is to elucidate the novel function of APP as a gliogenic factor and
specific glial differentiation mechanism, associated with sAPP-induced glial
differentiation of neural stem cells. The proposed study is innovative, since our research
may elucidate novel function and specific molecular mechanism of APP in stem cell
biology and may also provide perspective into understanding the mechanism of
pathophysiology of neurodegenerative diseases such as AD. Thus, our study is
significant because it will provide a vast knowledge of the novel function and
mechanisms of APP during HNSC differentiation and this information will be crucial for
developing innovative strategies for the prevention and treatment of AD, including
regulation of APP level, interference of APP catabolism by manipulating specific signal
cascade and/or suppression of IL-6 and/or Notch signaling by blocking the effect of
APP.

13

THE AMYLOID PRECURSOR PROTEIN INDUCES GLIAL
DIFFERENTIATION OF HUMAN NEURAL STEM CELL

Introduction
The discovery of multipotent neural stem cells (NSCs) in the adult brain, suggesting that
the regeneration of neurons can occur throughout life, has brought revolutionary
changes in the theory of neurogenesis 57. Neural stem cells have been isolated from
embryonic and adult mammalian 58, 59 tissue including the human central nervous
system (CNS) 60. These cells can be propagated in vitro using a serum-free medium
containing epidermal growth factors (EGF) and basic fibroblast growth factors (FGF-2)
61

. Many studies have shown that NSCs can be transplanted and incorporated into the

developing mammalian brain and can differentiate into neuronal and glial cells 62-64.
Even in the adult brain, at least some environmental cues seem to remain, as was
shown for the rostral migratory system, where stem cells extensively migrated from the
subventricular zone (SVZ) to the olfactory bulb 65 and to cognitively relevant brain
regions 66. In vitro cultivated and transplanted NSCs migrated using routes similar to
endogenous NSCs and then were differentiated in the adult brain. These cells also
showed a pattern of broad distribution in the cortex and hippocampus 67. Moreover,
transplanted animals showed improved cognitive functions and functional synapse
formation, implying that these cells are functionally capable of being incorporated into
the existing neural network 67, 68. While essential factors for the migration of neuroblasts
during embryonic development have been studied extensively in the past, it is still
unclear if these factors are also responsible for NSC migration in the adult brain. So far,
14

it has been suggested that polysialylated NCAM69, Eph/ephrin signaling 70, and b1
integrins 71 are the involved in neuronal chain migration. Additionally, our recent study
indicates that reelin, an extracellular matrix protein required for cortical patterning during
development, also affects NSC migration in the adult 72.

Many functions have been attributed to the amyloid precursor protein (APP), including a
role as a kinesin I cargo receptor 73. Nevertheless, APP-knockout mice are viable and
display only a minor phenotype 74, 75, suggesting that APP function both during
development and later in the maturing process can be at least partially compensated by
its family members [e.g., amyloid precursor-like protein 1, 2 (APLP1, APLP2)] 76.
Several studies have shown that APP has growth factor-like properties and can
increase proliferation 77, or together with the cytosolic adaptor protein Fe65 can
enhance cell motility in cell culture models 78. Moreover, crystal structure of the heparinbinding N-terminal domain of APP shows a growth factor-like domain structure,
supporting evidence of growth factor as a function of APP 27.

Here we report that APP is necessary for the migration and differentiation of HNSCs
using well-defined in-vitro culture differentiation model by eliminating exogenous factors
79

. Our data, i.e., HNSCs transplanted into APP-knockout mice showed significantly less

migration compared to transplanted wild-type controls, suggesting that APP may
function as a crucial cue in vivo during adult neurogenesis. Moreover, since excessive
environmental APP induced gliogenesis in HNSCs, these results implicate a deficiency
of stem cell biology by altered APP metabolism in Alzheimer’s disease (AD) pathology.
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Materials and methods

TUNEL assay
The Fluorescein Apoptosis Detection System (Promega, Madison, WI) was used to
assay the DNA fragmentation of HNSCs at 3 DIV. The protocol was followed according
to the manufacturer’s suggestions with only minor modifications. Briefly, HNSCs were
fixed in methanol at -20°C for 20 min. HNSCs were permeabilized in 0.2% Triton X-100
solution in PBS for 5 min, and equilibrated for 10 min with equilibration buffer. The TdT
enzyme reaction with fluorescein-12-dUTP was performed at 37°C in a dark humid
chamber for 60 min. All the nuclei of HNSCs were counter-stained by propidium iodide
(red) and the DNA fragmentation-positive cells were stained in green.

This study was performed under IRB protocol #2001-0316, which meets the criteria for
exemptions defined in the U.S. Department of Health and Human Services Regulations
for the Protection of Human Subjects (45 CFR 46). Optimized conditions for propagation
and maintenance of HNSCs have previously been described in detail 61, 67, 79. Briefly,
HNSCs were cultured in serum-free supplemented growth medium consisting of HAMSF12 (Gibco, BRL, Burlington, ON), antibiotic-antimycotic mixture (Gibco), B27
supplement (Gibco), human recombinant FGF-2, EGF (R&D Systems, Minneapolis,
MN), and heparin (Sigma, St. Louis, MO) and incubated at 37°C in a 5% CO2
humidified incubation chamber (Fisher, Pittsburgh, PA). Human NSCs were
differentiated in serum-free basal medium Eagle (BME, Gibco), which contains Earle’s
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salt and L-glutamine in the absence of FGF-2 and EGF without the addition of other
extrinsic differentiation factors.

sAPP preparation
APP cDNA comprising nucleotides -2 to 2358 in expression vector pORFex13 was a gift
from Dennis Selkoe. DNA encoding the sequence from leu18 to lys613 human APP695
was amplified by PCR using following primers : 5’-CTG GAG CTA CCC ACT GAT-3’and
5’-CTT CAA GTA GTA GTT TTT ACT-3’. The DNA fragment was gel-purified using a
GeneClean II (Bio 101) kit, then cloned into the Pml 1 site of the pPICZ expression
vector (Invitrogen) downstream of the pichia pastoris alcohol oxidase (AOX1) promoter.
To transform pichia pastoris, DNA was linearized with Pme I, mixed with pichia pastoris
strain SMD1168 (Invitrogen), and electroporated. Expression was induced by exposure
to methanol for 29 hr as described in the Invitrogen instruction manual. After induction,
the culture supernatant was filtered to remove any residual particles, and then loaded
on a 5 ml heparin-sepharose column (Amersham Pharmacia Biotech). The column was
washed with 0.01 M sodium phosphate buffer, pH 7 until no protein was detected in the
outflow. Then a 100 ml, 0-2 M linear NaCl gradient in 0.01 M sodium phosphate pH 7
buffer was applied to the column. The purified truncated form of sAPP695 was
sequenced and C-terminal carboxypeptidase analysis revealed it was truncated at
amino acid 505.
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Stereotactic injection of HNSCs into mice
Mature (3-4 month old) male mice (8 in each group) were deeply anesthetized with
sodium pentobarbital (50mg/kg, i.p.). Using the bregma as a reference point, about 105
of HNSCs preincubated with BrdU (3µM for 3 days) were slowly injected into the right
lateral ventricle (AP -1.4; ML 1.8; DV 3.8mm) of the brain using a stereotaxic apparatus
(David Kopff). Immunosuppressant was not given to the animals. All animal experiments
were conducted under Animal Protocol #00-184 approved by the Animal Care
Committee of the University of Illinois at Chicago. Four weeks post-transplantation,
animals were sacrificed and the brains were removed for analysis with
immunohistochemistry.

Immunohistochemistry
Detailed methods for immunohistochemistry were previously described11,24. Briefly, after
fixation, samples were washed in phosphate-buffered saline with 0.2 % Triton X
(PBST), then incubated in PBST containing appropriate normal sera. Next, the samples
were incubated overnight (up to 12 hr) with primary antibodies, and then incubated with
secondary antibodies for 1.5 hr in a dark humidified chamber after washing with PBS.
Next, the samples were washed thoroughly in PBS and coverslipped with
VECTASHIELD® DAPI Mounting Media (Vector). Primary antibodies: 4G8 monoclonal
antibody, mouse IgG2b (Senetek), 1:50; 6E10 monoclonal antibody, mouse IgG1
(Senetek), 1:50; 22C11 anti-Alzheimer Precursor Protein A4, mouse IgG (Chemicon),
1:100; anti-βIII-tubulin monoclonal, mouse IgG2b, clone SDL.3D10 (Sigma), 1:1000;
anti-GFAP goat anti-glial filament protein, N-terminal human affinity purified, goat IgG
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(Research Diagnostics Inc., Flanders, NJ), 1:400. Secondary antibodies coupled to
FITC or TRITC were purchased from Jackson Immuno Research.

RT-PCR analysis
Total RNA was extracted from the cells with Trizol reagent (Invitrogen) according to the
manufacturer’s protocol. One µg of the total RNA was reverse-transcribed (RT) and
amplified by the SuperScriptTM ONE-STEPTM RT-PCR system (Invitrogen) with the
following primers: GFAP (+) 5’-AAGCAGTCTACCCACCTCAG-3’, (-) 5’ATCCCTCCCAGCACCTCATC-3’; APP (+) 5’CTTGAGTAAACTTTGGGACATGGCGCTGC-3’, (-) 5’-GAACCCTACGAAGAAGCC-3’;
LIF (+) 5’-CTGTTGGTTCTGCACTGGA-3’, (-) 5’-GGGTTGAGGATCTTCTGGT-3’; Delta
(+) 5’-TGCTGGGCGTCGACTCCTTCAGT-3’, (-) 5’GCCTGGCTCGCGGATACACTCGTCACA-3’; Jagged-1 (+) 5’ACACACCTGAAGGGGTGCGGTATA-3’, (-) 5’-AGGGCTGCAGTCATTGGTATTCTGA3’; Hairy/Enhancer of split 1 (Hes1) (+) 5’-CGGACATTCTGGAAATGACA-3’, (-) 5’CATTGATCTGGGTCATGCAG-3’; β-actin (+) 5’-GACAGGATGCAGAAGGAGAT-3’, (-)
5’-TTGCTGATCCACATCTGCTG-3’. RT-PCR condition was a reverse transcription at
55˚C for 30 min; a pre-denaturation at 94˚C for 2min; 25-32 cycles of 94˚C for 15 sec;
55-56˚C for 30 sec and 72˚C for 30 sec; and a post-extension at 72˚C for 5 min. Cycle
number was adjusted in order to keep the PCR amplification in a log-phase for semiquantization. Ten µl of the reaction was separated in a 2% E-gel (Invitrogen).
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Results

HNSC differentiation is preceded by apoptosis
We have previously shown that under serum-free unsupplemented media conditions,
HNSCs grown as neurospheres migrate and differentiate into βIII-tubulin, glial fibrillary
acidic protein (GFAP), and O4 immunopositive cells, markers for neurons, astrocytes,
and oligodendrocytes, respectively 79. These results suggest that HNSCs are capable of
producing endogenous factors necessary for their own differentiation and survival. To
assess the migration and differentiation process in more detail, we employed a timelapse video microscopic study. During the early stages (1-3 days in vitro, DIV) of serumfree differentiation, differentiating HNSCs appear to reach out to some HNSCs, which
exhibit a shrunken morphology similar to cells undergoing apoptotic cell death (Figure
4). To further assess cell death type, we used the TUNEL assay to detect in situ DNA
fragmentation, an early marker of apoptosis, in HNSCs differentiated with/without
serum. Under serum-free differentiation conditions, the cells that displayed small
shrinkage followed by detachment from the neurosphere were TUNEL positive. In
contrast, fewer than 5% of TUNEL-positive cells that were detected had differentiated in
media supplemented with 10% fetal calf serum (Figure 5 a,b). The increase in apoptosis
without serum is probably due to growth factor deprivation, similar to that described for
neurons 80. Nevertheless, at later stages of serum-free differentiation, HNSCs migrate
and differentiate without further apoptosis, and are able to survive in unsupplemented
media for more than 3 weeks 79, indicating the existence of a self-supporting system.
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Thus, it seems likely that a factor(s) released from apoptotic cells may induce
differentiation and migration of HNSCs.
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Figure 4: Time-lapse video microscopy shows differentiating HNSCs migrate toward
apoptotic cells at 2 DIV. Differentiating HNSCs (arrow) in a serum-free unsupplemented
medium migrate away from the neurosphere cluster (a). Interestingly, these cells extend
their processes onto nearby morphologically shrunken cell(s), which are apparently
apoptotic cells (b), followed by a retraction of the processes (c), which are now attached
to the apoptotic cells (d), back into the neurosphere cluster (e). This response of
differentiating HNSCs to the apoptotic cells strengthened the possibility that some
component(s) of apoptotic cells serve as a “factor(s)” capable of influencing the
physiological activity of differentiating HNSCs.
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Figure 5: APP expression is increased in apoptotic cells under the serum-free
differentiation condition. The TUNEL signal for DNA fragmentation increased at 3 DIV,
indicating HNSCs underwent much greater degree of apoptotic cell death (yellow)
during differentiation in a serum-free unsupplemented medium (a) compared with serum
differentiation conditions (b). All these nuclei of HNSCs were counter-stained by
propidium iodide (red) and the DNA fragmentation positive cells were visualized with
fluorescein (green). All these nuclei of HNSCs were counter-stained by DAPI (c, blue)
The TUNEL signal (d, green) and immunoreactivity for APP recognized by 22C11
monoclonal antibody (e, red) are co-localized in the shrunken morphology cell in the
serum-free differentiation condition (f).
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APP is increased in apoptotic HNSCs
Since it is known that APP levels are elevated in apoptotic cells 81, we tested whether
this is also true for HNSCs under serum-deprived conditions. We combined the TUNEL
assay and immunocytochemistry with a well-characterized monoclonal antibody
recognizing the N-terminal growth factor-like domain of APP (22C11). Under serum-free
conditions, TUNEL-positive cells showed strong expression whereas non-apoptotic cells
exhibited only background levels of APP (Figure 5c-e), indicating that APP levels are
also elevated in apoptotic HNSCs.

APP involved in migration or differentiation of HNSCs
We further hypothesized that under serum-free conditions, APP derived from apoptotic
HNSCs might serve as a migration and differentiation factor for neighboring HNSCs. To
investigate if APP is involved in the migration and differentiation process, we tested
whether the 22C11 antibody inhibits APP function on HNSC migration. We treated
HNSCs with a variety of concentrations of 22C11 under serum or serum-free
differentiation conditions for 3 days. The addition of 22C11 (500 ng/ml) completely
inhibited migration and differentiation of HNSCs under serum-free unsupplemented
conditions (Figure 6). In contrast, 22C11 treatment did not affect the migration of
HNSCs when fetal bovine serum was added to the culture (data not shown). This result
suggest that APP may be involved in the induction of the differentiation and migration of
HNSCs, whereas fetal calf serum contains (possibly independent of APP) many other
factors promoting migration and differentiation.
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To investigate whether the N-terminal secreted form of APP might be sufficient to
induce migration of HNSCs, we treated HNSCs with an exogenous recombinant human
secreted APP (sAPP) produced in yeast 82, which contained 95% sAPP695T (ending at
amino acid 505 of 695) and 5% sAPP695 (ending at the alpha cut). The addition of
recombinant sAPP to cell culture media dose-dependently (25, 50 and 100 ng/ml)
increased migration and differentiation of HNSCs (Figure 7 a-d) under serum-free
conditions. At the highest dose (100ng/ml), neurospheres were completely absent.
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(d)

Figure 6: Treatment with 22C11 antibody recognizing the N-terminal of APP dosedependently inhibited differentiation of HNSCs in non-serum unsupplemented media.
The panels show the typical differentiation pattern of HNSCs under treatment with
22C11 (a; control, b; 125 µg/ml, c; 250 µg/ml, d; 500 µg/ml) at 3DIV.
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sAPP increases gliogenesis of HNSCs
We also characterized the cell population of sAPP-treated HNSCs at 5 DIV under
serum-free conditions by double-immunofluorescent labeling of GFAP and βIII-tubulin
(Figure 7 e-h). Treatment with sAPP dose dependently (25, 50, and 100 ng/ml)
increased the population of GFAP-positive cells from an average of 45% in controls (no
sAPP) to an average of 83% with the highest concentration of sAPP treatment (100
ng/ml at 5 DIV).

Interestingly, the lowest dose of sAPP treatment (25 ng/ml) increased both glial and
neuronal differentiation. However, higher doses of sAPP (50 and 100ng/ml) dosedependently decreased βIII-tubulin-positive cells (neurons) in the total population of
differentiated HNSCs, from an average of 51% in controls to an average of 13% with the
highest concentration of sAPP treatment (Figure 7i). Expressions of genes related to
JAK/STAT signaling (LIF, CNTF, JAK1 and STAT3, Figure 8A) and Notch signaling
(Delta, Jagged1 and Hes1, Figure 8B) were increased in NT-2 cells treated with sAPP
(100 ng/ml) for overnight. This result indicates activation of astrocytic differentiation
mechanisms. Although the mechanism for the glial promoting effect of sAPP on HNSCs
is not yet clear, APP may increase glial differentiation by influencing the cell fate
decision of HNSCs. Since sAPP treatment did not increase the apoptosis related gene
expression in HNSCs, selective death of proneural progenitors in the neurospheres can
be ruled out (Fig. 8C).
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Figure 7: Secreted amyloid precursor protein (sAPP) alters migration and differentiation
of HNSCs. Treatment of HNSCs culture with recombinant sAPP for 5 days dosedependently (a; control, b; 25 ng/ml, c; 50 ng/ml and d; 100 ng/ml) increased the
migration and differentiation of HNSCs under the serum-free unsupplemented condition.
The cell population of sAPP-treated HNSCs at 5 DIV in the serum-free differentiation
condition was further characterized by double immunofluorescence staining with GFAP
(red) and βIII-tubulin (green) markers for astrocytes and neurons, respectively. All nuclei
were counterstained with DAPI (blue). The panels show typical morphology and
differentiation patterns of HNSCs in e; control culture and cultures treated with f; 25
ng/ml, g; 50 ng/ml and h; 100 ng/ml of sAPP. At low dose of sAPP (25 ng/ml), increased
glial (red) and neuronal (green) differentiations were observed compared with the
control (f). At a higher dose of sAPP treatment, many glially differentiated HNSCs (red)
were observed (g and h).
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Figure 8: Gene expression pattern after sAPP treatment in neuronal progenitors.
Expressions of genes related to JAK/STAT signaling (LIF, CNTF, JAK1 and STAT3)
and Notch signaling (Delta, Jagged1 and Hes1) were increased in NT-2 cells treated
with sAPP (100ng/ml) for overnight. This result indicates activation of astrocytic
differentiation mechanisms. However, genes associated with apoptosis (Bcl-2 and BAX)
did not change.
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HNSCs migration and differentiation is reduced in APP-knockout mice
Based on our in vitro data, we further investigated whether APP might have an impact
on the migration or differentiation of NSCs in adults in vivo. To address this question,
we transplanted HNSCs into the brains of APP knockout 74 and control mice at 3
months of age. To differentiate between host and transplanted cells, HNSCs were
labeled in vitro by the incorporation of bromodeoxyuridine (BrdU) into the nucleus DNA
before transplantation. These labeled cells (about 105) were subsequently injected
unilaterally into the cerebral lateral ventricle of c57/black wild-type (WT) and APPknockout mice. Immunohistochemical examination of wild-type brain sections 4 weeks
after transplantation revealed migration and differentiation patterns similar to our
previous study with HNSCs transplanted into aged memory-impaired rats 67. Cells
distributed bilaterally in the singular and parietal cortexes (layer II, IV and V) (Fig. 9a)
and hippocampus (CA1, CA2 and dentate gyrus) (Fig.9c) were intensely and
extensively immunopositive for BrdU and human βIII-tubulin. The transplanted HNSCs
also differentiated into GFAP-immunopositive cells that co-localized with the neuronal
fibers of layer III in the cortex (Fig.9e). These donor-derived BrdU-immunopositive cells
were much larger than the host brain cells. We did not detect the above-mentioned
morphologies and distributions of βIII-tubulin- or GFAP-positive cells in wild-type control
mice that had not received HNSC transplantation.

Although transplanted HNSCs in APP-knockout mice also differentiated into βIII-tubulinand GFAP- positive cells, the distribution and migration patterns were not symmetric
30

and differentiated cells were far fewer compared to injected wild-type mice. Despite the
rather uniform βIII-tubulin-positive cell distribution and structure in the hippocampus of
APP-knockout mice (Fig. 9d), βIII-tubulin-positive HNSCs were only detected near the
injection site of the cortex and lacked apical dendrites (Fig. 9b). These results indicate
that APP plays an important role in neurogenesis in the adult brain.
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(a)
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Figure 9: HNSCs transplanted into the APP knockout mice brain show fewer migrations
and differentiations compare with cells transplanted into wild-type control mice. To
distinguish HNSCs from the host cells HNSCs were prelabeled by BrdU in vitro before
unilateral ventricle injection. We immunostained the brain with βIII-tubulin, GFAP, and
BrdU, markers for neurons, astrocytes, and transplanted HNSCs at 4 weeks after
injection, respectively. All nuclei were counterstained with DAPI (blue). In wild-type
mice, BrdU (red) and βIII-tubulin (green) immunopositive cells were distributed
bilaterally in the parietal cortexes (a) and pyramidal layer of the hippocampus (c)
indicating the neuronal differentiation of transplanted HNSCs. HNSCs also differentiated
into GFAP-immunopositive cells (red) that associated with the βIII-tubulin (green)
stained neuronal fibers of layer III in the cortex (e). The differentiation and distribution
patterns of the transplanted HNSCs are similar to those we found in our previous
transplantation study with rats11.In APP knockout mice, βIII-tubulin-positive cells (green)
with BrdU (red) positive nuclei, neurally differentiated HNSC-transplants were only
detected near the injection site in the cortex and these cells showed abnormal
morphologies (b). In the hippocampus, although the number of HNSC-derived cells was
reduced, βIII-tubulin and BrdU-immunopositive cells had quite similar positioning and
structure to these cells found in wild-type mice (d).
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Discussion
Our study clearly showed that APP function is relevant for HNSC migration and
differentiation in vitro and in vivo. We found that under non-serum differentiation of
HNSCs, APP levels are elevated in apoptotic cells. This result is consistent with other
studies showing that damaged neurons and neurons committed to apoptosis are
strongly immunopositive for APP 83, 84. Time-lapse observation of HNSC cultures under
non-serum differentiation conditions showed migration of differentiating HNSCs toward
the apoptotic cells in vitro. We demonstrated that treatment with recombinant sAPP
promoted the migration and differentiation of HNSCs, and 22C11 antibody-mediated
neutralization of APP inhibited these effects in a dose-dependent manner. Since
amyloidogenic fragments produced from APP are reported to be released into the
extracellular space from neuronal cells under serum-deprived conditions 80, we
hypothesize that under serum-free differentiation conditions, APP released from
apoptotic cells serves as a differentiation and/or migration factor for neighboring
HNSCs. Although the mechanism of 22C11-mediated inhibition of the migration and
differentiation of HNSCs is not clear, since the epitope of 22C11 lies within the growth
factor-like domain of APP, 22C11 may prevent receptor or ligand interactions by binding
to biologically active sites of APP. It is known that sAPP activates MAPK (ERK) in PC12
cells via the ras pathway 85. Ras in turn, can activate rac 86, a rho-family GTPase
controlling lamellipodia formation through a focal complex assembly, and thereby also
activating cell motility. Focal complex assembly is an integrin-mediated process
requiring extracellular matrix and rho/rac activity87. Sabo and colleagues 78 have shown
that APP can enhance cell motility in MDCK cells in association with Fe65, which
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colocalizes with APP at focal contacts. Since Fe65 over expression is known to
increase secretion of APP 88, one could argue that APP secreted from neighboring cells
act as a migrational cue through focal adhesion assembly. Since b1-integrins have been
shown to be necessary for the chain migration of neuroblasts 71, the connection
between integrin-mediated migration and APP could be a clue for understanding the
mechanism of the regulation of stem cell motility by APP. In contrast to another study
showing that sAPP significantly enhanced proliferation of neural stem cells 89, we did
not observe this effect in our studies, probably because our assay was done under nonserum conditions without any proliferation factors.

Besides increasing differentiation and migration, a high concentration of sAPP
increased the glial cell population of differentiated HNSCs in vitro, indicating that the
over-production of APP fragments may influence the cell fate decision of HNSCs and
reduce neural differentiation. Another possibility is that higher concentrations of sAPP
may eliminate HNSC populations differentiating into neurons, since high APP
expression in neuronal cell lines is reported to cause apoptotic cell death by caspase-3
activation 90, although the latter possibility can probably be excluded because sAPP
treatment did not increase expression of apoptosis related genes in HNSCs.

Gene expression data after sAPP treatment of the cells also show increased expression
of genes related to Notch and JAK/STAT signaling indicating activation of these
cascades. Since these signaling cascades are known to involve in glial differentiation of
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stem cells, sAPP might affecting on these cascades to induce glial differentiation of
HNSCs. However, detailed studies are needed to confirm the mechanism of action.

Recently, Bahn et al., reported that NSCs from Down's syndrome patients differentiated
into astrocytes rather than neurons 56. They have also reported a morphological
abnormality of neurally-differentiated NSCs, which we have also seen in HNSCs
transfected with wtAPP. Since Downs' syndrome patients have inherited three copies of
APP that resides on chromosome 21, this abnormal differentiation may result from an
overdose of the APP gene. Furthermore, since Down's patients develop AD by age 40,
these findings might also have implications in AD pathology. Although it is not clear
whether adult neurogenesis is essential for normal cognitive function in aging, it is
tempting to speculate that the altered APP metabolism that impairs proper NSC
migration and differentiation could be a part of pathological process of AD, since aged
transgenic APP mice exhibit neocortical neuronal loss 91. Furthermore, although the rate
of neurodegeneration in the adult brain may be minimal, it may be that in the long run,
such a deficit might significantly reduce normal brain function. In addition to these
drawbacks, transplantation therapy of AD with HNSCs may not be effective in an
environment where APP metabolism is altered and might lead to excessive gliogenesis.
Thus, we may have to consider the regulation of APP processing to develop effective
HNSC transplantation therapy in AD patients.

Regulation of stem cell biology by APP raises a question regarding Ab immunization,
which may also reduce APP fragments. Could Ab immunization be helpful for
35

maintaining stem cell function in AD? Our current study has shown for the first time that
APP is one of the factors required for HNSC migration in the adult brain. Migration of
transplanted HNSCs to the cerebral cortex was markedly reduced in APP-knockout
mice compared to wild-type controls. Since migration from the subventricular zone to
the neocortex could be found in adult macaques 66, lack of APP expression in APPknockout mice might be a major factor in preventing the migration of HNSCs into this
region, indicating that APP regulates NSC migration in the adult brain. Although it is
conceivable that APP expression in transplanted HNSCs may partially compensate for
the APP deficit in the host brain, this effect seems to be minimal, since the absence of
environmental APP clearly alters the migration pattern of transplanted HNSCs. Thus,
APP might function as an environmental cue rather than as a cell-cell contact
mechanism. In mammals, APP is part of a gene family comprising three paralogues:
APP, APLP1, and APLP2. Evolutionary studies have revealed a remarkable homology
between these proteins, specifically in the N-terminal and C-terminal domains 14, 92.
Additionally, mouse double-knockouts of both APP and APLP2 result in 80% mortality
during the first week postnatally 93, indicating that APLPs may compensate for the lack
of APP in the APP-knockout mouse. The successful migration of transplanted HNSCs
into the hippocampus of APP knockout mice, as we have observed in the current study,
may thus be explained by the redundant function of APP, APLP1, and APLP2. This
redundancy is also supported by the finding that APLP1 and APLP2 mRNAs are highly
abundant in the granule cells of the dentate gyrus in humans 94. It would be interesting
to extend our studies to double-knockout mice to confirm this hypothesis. These results
indicate that environmental or sAPP factors may be important in regulating the migration
36

and differentiation of HNSCs in the adult brain. Since HNSCs may play important roles
in neurodegeneration, if APP is indeed involved in the regulation of HNSCs as we
propose, destruction of the APP system may jeopardize the maintenance of normal
adult brain function.
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AMYLOID PRECUROSR PROTEIN IS INVOLVED IN STAUROSPORINE
INDUCED GLIAL DIFFERENTIATION OF NERUAL STEM CELLS

Introduction
Human embryonic teratocarcinoma cells (NT-2/D1) derived from a testicular germ cell
tumor have been intensively used as an experimental model for investigating neural
differentiation 95-97. Unlike post-mitotic CNS neurons or neuroblastoma, NT-2/D1 cells
still possess some multipotency and distinctive developmental characteristics, which
resemble the nature of neural stem cells 98. By treating with all-trans retinoic acid (RA),
NT-2/D1 cells are known to progressively differentiate into post mitotic neurons in 3-5
weeks, expressing full neuronal characteristics and capable of forming functional
synapses 99, 100. Recently, RA treatment has also been reported to differentiate NT-2/D1
into astrocytes (NT2/A) 99, which express astrocyte specific markers such as glial
fibrillary acidic protein (GFAP), astrocyte-specific glutamate transporter-1 (GLT-1)/
excitatory amino acid transporters (EEAT)-2 and aspartate transporter (GLAST)/EAAT-1.

Staurosporine (STS), indolo (2, 3-alpha) carbazole, has been extensively used as a
protein kinase C inhibitor 101 or apoptosis inducer in neuronal precursors 102, neurons 103,
and other tumor cell lines. However recent studies indicate STS also inhibits cell
proliferation and induces neuronal and glial differentiation of murine embryonic stem
cells 104, PC12 pheochromocytoma 105, and C6 glioblastoma 106. Although the target and
mechanism of the tropic effects of STS remains to be determined, STS may have
properties not only as an apoptotic inducer but also as a differentiation inducer. In the
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current study, we try to elucidate mechanisms of STS-induced astrocytic differentiation
using NT-2/D1 cells.

The amyloid precursor protein (APP) is a 695- to 770-amino acid, membrane spanning
glycoprotein. To date, the cytotoxicity of Aβ peptides, generated from APP by sequential
cuts with γ- and β-secretases, has been extensively studied since Aβ deposition is a
major pathophysiology of Alzheimer’s Disease (AD) 107. While physiological function of
APP has not been well documented, structure of APP suggests that APP might function
as a receptor via Go binding domain 108, or as a ligand via soluble N-terminal domain 28,
109

. Secreted type of APP (sAPP) promoted neurite outgrowth of primary neuronal

cultured cells 28 as well as proliferation of neural stem cells 109. Over expression of APP
reduced the number of apoptotic neurons deprived of NGF in dorsal root ganglion 110,
which may occur through p38 MAPK-dependent phosphorylation and activation of
myocyte enhancer factor-2 111. These results indicate that APP has properties of growth
and anti-apoptotic factors. Here, we demonstrate that APP is playing an important role
in STS-induced astrocytic differentiation of NT-2/D1 cells.

Materials and methods

Reagents and antibodies
STS (Sigma), PD098059 (Sigma) and SB239060 (Calbiochem) was dissolved in
dimethyl sulfoxide and stored at –80˚C until use. Primary antibodies: rabbit anti-GFAP
antibody (Promega); mouse anti-APP antibody (22C11) (Chemicon); mouse anti-ERK
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antibody (BD Transduction Laboratory); and mouse anti-phospho-ERK1/2
(pT202/pY204) antibody (BD Transduction Laboratory. Secondary antibodies: antimouse IgG and anti-rabbit IgG horseradish peroxidase-conjugated antibodies (Jackson
Immunoresearch Laboratory) were used.

Cell culture
The NT2/D1 cells were seeded (5x106 cells per 150 mm petri dish) in Dulbecco’s
modified Eagle’s medium with F-12 (DMEM/F-12; Invitrogen) supplemented with 10%
heat inactivated fetal bovine serum (Novacell), 1% antibiotic-antimycotic (Invitrogen), 4
mM glutamine (Invitrogen) and maintained in a humidified atmosphere of 5% CO2/95%
air at 37˚C. The cells were passed twice a week by short exposure to trypsin/EDTA
(Invitrogen). For the experiments, 1x106 NT-2/D1 cells were plated in a 6 well tissue
culture plate and subsequently treated with 10 or 40 nM STS. Cells were rinsed twice in
ice-cold phosphate-buffered saline (PBS, pH7.4) then mRNA and protein samples were
extracted for further analysis. Enhanced green fluorescent protein (EGFP) expression in
the cells were detected as green fluorescence signals under a microscope (Leica,
model DMRB) after fixing with 4% Para formaldehyde.

siRNA preparation
Human APP695 (Genbank access number: A33292) mRNA target sequences were
designed using Ambion target finder software. The mRNA target sequences of human
APP695 was 5’- AATCTTTGGAACAGGAAGCAG-3’ (1094-1114). siRNA PCR products
were synthesized using a SilencerTM Express kit (Ambion). Then, silencing efficacy was
40

determined using RT-PCR. As a control, we prepared EGFP siRNA PCR products
(accession number: U55763, target sequence: 106-127) as follows. In the first round
PCR, hU6 promoter (GenBank accession #M14486, gene sequence 64-355) and 27 nt
of U6 5’-coding sequence was amplified with a primer set (U6-F: 5’TCTTTGGAATTCAAGGTCGGGCAGGAAGAGGGCCTA-3’, U6-R: 5’CGCGGATCCTAGTATATGTGCTGCCGAAGC-3’) using plasmid pUC-hU6 112 as a
template. Simultaneously hairpin-siRNA for EGFP gene consists of 21 nt sense strand
of siRNA, 9 nt spacer and 21 nt antisense strand of siRNA was generated by PCR using
another primer set (siEGFP-F: 5'-CGC GGA TCC GGC GAT GCC ACC TAC GGC AAG
CTC GAG ATC-3', siEGFP-R: 5'-GCT CTA GAG GCG ATG CCA CCT ACG GCA AGG
ATC TCG AGC T-3'). After 100-times dilution, first round PCR products were mixed and
used as template for the second round PCR reaction. Since 5’ end of siEGFP-F primer
contains complementary sequence to 3’ end of hU6 promoter region, the second round
PCR using U6-F primer and siEGFP-R primer produced hU6-siEGFP. The first and
second round PCR reaction condition were both pre-incubation at 95˚C for 5 min; 35
cycles of 95˚C for 40 s, 55˚C for 30 s and 72˚C for 30 s; and post-extension at 72˚C for
5 min. To produce PCR fragment containing hU6 promoter with a random sequence for
using as a nonspecific siRNA in the cells, we used a primer set U6-F and U6-R1 (5'AAA AAT TCT AGA TGT AAA AAT AGT GTT GTG TGC CTA GGA TAT GTG CTG
CCG AAG CGA GCA C-3’) using plasmid pUC-hU6 as a template.
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Transfection
Transient transfection of pEGFAP-C1 (BD Clontech), pCEP-APP-GFP, pCEP-APP695
(kindly provided by Dr. Beth Ostaszewski, Harvard Medical School), pGFAP-GFP-S65T
(kindly provided by Dr. Albee Messing, University of Wisconsin Madison) and siRNA
PCR fragments (U6-random, siGFP and siAPP) was performed with LipofectamineTM
2000 (Invitrogen) on sub confluent NT-2/D1 cells in a 6-well culture plate, according to
the manufacturer's protocol. Transfection efficiency in NT-2/D1 cell was determined by
transfection of 0.5 µg of pEGFP-C1, and it was generally around 80%.

RT-PCR analysis
Total RNA was extracted from the cells with Trizol reagent (Invitrogen) according to the
manufacturer’s protocol. One µg of the total RNA was reverse-transcribed (RT) and
amplified by the SuperScriptTM ONE-STEPTM RT-PCR system (Invitrogen) with the
following primers: GFAP (+) 5’-AAGCAGTCTACCCACCTCAG-3’, (-) 5’ATCCCTCCCAGCACCTCATC-3’; APP (+) 5’CTTGAGTAAACTTTGGGACATGGCGCTGC-3’, (-) 5’-GAACCCTACGAAGAAGCC-3’;
GLT-1 (+) 5’-GACAGTCATCTTGGCTCAGA-3’, (-) 5’-AATCCACCATCAGCTTGGCC-3’;
GLAST (+) 5’-CTGCTCACAGTCACCGCTGT-3’, (-) 5’-AGCACGAATCTGGTGACGCG3’; EGFP (+) 5’-CAAGGACGACGGCAACTACAAGAC-3’, (-) 5’GCGGACTGGGTGCTCAGGTAGTGGT-3’; β-actin (+) 5’GACAGGATGCAGAAGGAGAT-3’, (-) 5’-TTGCTGATCCACATCTGCTG-3’. RT-PCR
condition was a reverse transcription at 55˚C for 30 min; a pre-denaturation at 94˚C for
2min; 25-32 cycles of 94˚C for 15 sec; 55-56˚C for 30 sec and 72˚C for 30 sec; and a
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post-extension at 72˚C for 5 min. Cycle number was adjusted in order to keep the PCR
amplification in a log-phase for semi-quantization. Ten µl of the reaction was separated
in a 2% E-gel (Invitrogen).

Immunoprecipitation and western blot analysis
Protein samples were prepared by lysing the cells using an ice-cold lysis buffer consist
of 1% NP40, 150 mM NaCl, 50 mM Tris pH8.0 and Complete Protease Inhibitor Tablets
(Boehringer). The protein concentration of each sample was measured by Bio-Rad
protein assay (Bio-Rad). Lysates were immunoprecipitated with an antibody against
APP, GFAP, and ERK molecules using protein A-Sepharose (Amersham Bioscience).
Then, precipitates and, in some cases, cell lysates were heated at 70ºC for 10 min in a
sample loading buffer and separated on NuPAGETM 4-12 % Bis-Tis Gel (Invitrogen) for
45 min at 200 V and transferred to a PVDF membrane (30V, 60 min). Membranes were
blocked with 5% skim milk in PBS for 1h at room temperature and probed at 4˚C
overnight with primary antibody in 5% skim milk. The membranes were washed 3 times
for 5min each with PBS containing 0.05% Tween 20 (pH7.4) and then incubated with
horseradish peroxidase-conjugated secondary antibodies in 5% skim milk for 2h at RT.
After 3 times washing with PBS containing 0.05% Tween 20, immunoreactive bands
were visualized by using ECL plus (Amersham Bioscience) chemiluminescence
reagent.

Cloning and expression of the recombinant human APP695
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We amplified human APP695 gene from pCEP-APP695 by PCR using EPPENDORF®
HotMasterMix (2.5×, Eppendorf). The commercially synthesized primers were R-hAPP
(+): 5’-CACCCTGGAGGTACCCACTGAT-3’ and R-hAPP (-): 5’TCATTTTTGATGATGAACTTG-3’ for protein expressed with a His tag at the N
terminus. The PCR product was separated by gel electrophoresis on a 1.2% E-gel
(Invitrogen), and the appropriate band was extracted using a gel extraction kit
(Quiagen). Then, blunt-end directional cloning was performed by a topoisomerase
reaction into a pET100 vector (Champion pET Directional TOPO Expression and
Cloning Kit, Invitrogen). The gene insertion and its directionality as well as the integrity
of the pET100 vector were verified by the sequencing facility at the University of Central
Florida. BL21 Star DE3 (Invitrogen) competent cells were transformed for protein
expression and grown in Luria-Bertani broth at 37˚C to an absorbance ~0.8 at 600nm.
Then, protein expression was induced under ampicillin (50µg/ml) and 1 mM isopropyl-βthiogalactopyranoside at 37˚C for 4h. Cells were harvested by centrifugation at
10,000×g for 25 min.

Purification of human APP695
Cells were resuspended in lysis buffer [50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole, pH 8.0] and disrupted by sonication. Cell lysates were collected by
centrifugation (2000g at 4˚C for 20 min). The supernatant was directly applied to Ni-NTA
column (invitrogen), which is washed with a buffer solution containing 50 mM NaH2PO4,
300 mM NaCl, and 20 mM imidazole pH 8.0, to remove nonspecifically bound protein.
The His-tagged protein was eluted with buffer containing 50 mM NaH2PO4, 300 mM
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NaCl, and 150 mM imidazole pH 8.0. The purified protein was then stored at –20˚C. The
sample was more than 95% pure, as assessed by SDS-PAGE.

Image analysis
Gel or Western blot images were captured by KODAK Image Station 2000MM. Optical
density of the target bands were analyzed using ImageJ (Ver 4.1, NIH) and expressed
in mean±SD from experiments performed in triplicates.

Results

Induction of glial cell like morphological change of NT-2/D1 cells by STS
As a further test for function of STS as a differentiation inducer, we analyzed
morphological changes after STS treatment. NT-2/D1 cells grew as a monolayer culture
of neuroepithelial cells with a high nuclear to cytoplasmic ratio and prominent nucleoli
resembling embryonic carcinoma cells (Figure 10A-a). Morphological changes started
right after day 1 of treatment with 40 nM STS (Figure 10A-b). Dramatic change of
morphology occurred after 7 days treatment of 40 nM STS (Figure 10A-c) and these
changes continued during 14 days treatment of STS (Figure 10A-d). Based on
morphological features, protoplasmic and polygonal irregular star-like cells, STS treated
cells showed distinctive astrocytic cell morphology (Figure 10A-c, d), indicating that STS
treatment induced astrocytic differentiation of NT-2/D1 cells.
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GFAP expression in STS-treated NT-2/D1 cells
Although physiological function of GFAP during astrocytic differentiation is still unclear,
GFAP has been used as a typical maker for astrocytic differentiation 113, 114. To
characterize the morphological changes in NT-2/D1 after STS treatment, we analyzed
GFAP expression in these cells using RT-PCR (Figure 10B). Levels of GFAP mRNA
were increased by STS-treatment compared to the basal level of GFAP mRNA in
control cells with time dependent manner up to 24 hours. These cells also expressed
astrocyte-specific glutamate transporter-1 (GLT-1)/ excitatory amino acid transporters
(EEAT)-2 and aspartate transporter (GLAST)/EAAT-1 (Figure 10C).

We also confirmed GFAP promoter activation by STS treatment using NT-2/D1
transfected with GFAP promoter driven GFP plasmid vector (pGFAP-GFP-S65T) as a
reporter system. As shown in Figure 10D and E, 10 nM STS treatment induced both
mRNA and protein expression (green fluorescence) of GFP. These results indicate that
STS induces astrocytic differentiation of NT-2/D1 cells.
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Figure 10: Morphological changes of NT-2/D1 cells and induction of astrocyte specific
gene expression by STS. (A) NT-2/D1 cells grew as a monolayer culture resembling
embryonic carcinoma cells (a, x100). Morphological changes started right after day 1 of
treatment with 40 nM STS (b, x100). Astrocyte like morphology was observed after 7
days (c, x100) and 14 days (d, x400) treatment with STS. (B) RT-PCR analysis of GFAP
gene expression in NT-2/D1 cells treated with 10 nM STS for 0, 6, 12 and 24 hrs shows
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time-dependent increase of GFAP gene expression. Expression of β-actin was
examined as a loading control. (C) RT-PCR analysis shows treatment with 10 nM STS
for 24 h induced astrocyte specific glutamate transporter expressions (GLT-1/EAAT-2
and GLAST/EAAT-1) in NT-2/D1 cells. (D) RT-PCR analysis of mRNA of GFP
transcribed by GFAP promoter in NT-2/D1 cells transfected with pGFAP-GFP-S65T
(1µg each) as a reporter system. After 2days, the cells treated with 10 nM STS for 24 h
expressed GFP gene. (E) Fluorescence image of GFP in NT-2/D1 cells transfected with
pGFAP-GFP-S65T with STS (a) and without 10 nM STS (b) treatment for 24h. Then
cells were fixed with 4% para formaldehyde and analyzed under the fluorescent
microscope.
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Increased gene expression level of APP during STS-induced astrocytic
differentiation
Both mRNA and protein expression of APP in NT-2/D1 time-dependently increased
after 10 nM STS treatment (Figure 11A and B). In addition, concentration of sAPP also
time-dependently increased in the media of NT-2/D1 cell culture (Figure 11B). Then,
the increased catabolism of APP showed the correlation with the GFAP expression in
the NT-2/D1 cells (Figure 11B). This result suggests that STS-induced APP expression
may have an important role in astrocytic differentiation of NT-2/D1 cells.

.
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Figure 11: Increased gene expression of APP during STS-induced gliogenesis. (A) RTPCR analysis of APP gene expression in NT-2/D1 cells treated with 10 nM STS. (B)
Western blot analysis of APP, sAPP and GFAP protein expression in NT-2/D1 cells
treated with 10 nM STS. Samples for APP and GFAP were isolated from the cell
lysates; sample for sAPP was isolated from the NT-2/D1 cell culture media. The
samples were subjected to immunoprecipitation with mouse-anti-APP Ab (22C11) or
rabbit-anti-GFAP Ab. Then the immunoprecipitants were analyzed by Immunoblot
analysis using a mouse-anti-APP Ab (22C11) or rabbit-anti-GFAP Ab. Western data
show time dependent increase of these proteins
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sAPP induced GFAP expression in NT-2/D1 cells
To determine whether expression of APP can affect stem cell differentiation, we applied
various amounts (0, 1, 10, and 100 ng) of recombinant APP695 protein in NT-2/D1 cells,
neural progenitor cell lines, overnight and examined GFAP expression. A distinctive
increase of GFAP expression was observed with a dose-dependent manner except
500ng APP treated cells compared to the control (Figure 12A). Although expression of
GFAP was somehow decreased in higher dose treated cells, still GFAP expression level
was higher than the control. We already reported STS enhances gene expression of
GFP by stimulating GFAP promoter activity (Figure. 10D and E). However, it wasn’t
clear whether STS has a direct affect on the GFAP promoter or GFAP promoter activity
is regulated by other factors, such as APP, which is induced by STS treatment. Thus,
we examined GFAP promoter activity by assessing GFP expression using NT-2/D1
cells transfected with GFAP promoter driven GFP expression vector (pGFAP-GFPS65T) (Figure 12B). When APP695 expression vectors (pCEP-APP695) were
overexpressed in reporter vector transfected cells, gene expression of GFP was
detected. Therefore, these results suggest that APP is involved in astrogliogenesis of
NT-2/D1 cells in STS treated condition.
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Figure 12: Increased GFAP expression in either treatment of APP and overexpression
of APP. (A) RT-PCR analysis of GFAP gene expression in NT-2/D1 cells treated with
various amount (0, 1, 10, and 100 ng) of recombinant APP shows dose-dependent
increase of GFAP gene expression. Expression of β-actin was examined as a loading
control. (B) RT-PCR analysis of mRNA of GFP transcribed by GFAP promoter in NT2/D1 cells transfected with pGFAP-GFP-S65T (1µg each) as a reporter system. Only
APP expression vector (pCEP-APP695) was co-transfected, expression of GFP mRNA
can be examined
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Gene silencing of APP expression suppresses GFAP expression
Recently small interference RNA (siRNA) has been extensively used for elucidating
specific functions of the gene of interest 115. To confirm the involvement of APP in STSinduced astrocytic differentiation, we investigated whether STS function in NT-2/D1 is
abolished by knocking-down the gene expression of APP using siRNA. We constructed
specific siRNA PCR products (siAPP-PCR), which specifically recognize APP. Small
interference APP-PCR significantly decreased protein expression of APP–GFP fusion
protein in NT-2/D1 cells transfected with pCMV-APP-GFP (Figure 13 A-d). Control PCR
products (U6-random sequence PCR) did not inhibit APP-GFP fusion protein
expressions.

Small interference APP PCR also showed significantly suppressed APP and GFAP
gene expressions in NT-2/D1 cells treated with STS, while control siRNA PCR products
(siGFP-PCR), which recognize GFP, didn’t suppress APP and GFAP expression
(Figure 13 B and C). These findings suggest that APP is a crucial molecule for
astrocytic differentiation of NT-2/D1 cells induced by STS treatment.
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Figure 13: Assessment of APP functions by RNAi for APP in NT-2/D1 cells. (A) A mocktransfected NT-2/D1 cells, as negative controls, show no auto fluorescent signal (a).
NT-2/D1 cells transfected with 1µg of pEGFP-C1, as positive controls, show significant
level of green fluorescent signals (b). NT-2/D1 cells in both c and d received
transfection of 1 µg of pCEP-APP-GFP to express APP-GFP fusion protein. Co54

transfection of 1 µg of U6-random PCR products expressing random sequence does not
suppress expression of the APP-GFP fusion protein (c). Co-transfection of 1 µg of
siRNA PCR products targeting APP significantly suppresses expression of the APPGFP fusion protein (d). Experiments were repeated at least three times with similar
results. (B) Silencing of APP reduced GFAP expression stimulated by 10 nM STS in
NT-2/D1 cells. Gene expression levels of APP and GFAP were assessed by RT-PCR in
NT-2/D1 cells treated with 10 nM STS were transfected with each 1 µg of siRNA of PCR
products targeting GFP (siGFP) or APP (siAPP) for 2 days. Transfection of siAPP but
not siGFP significantly reduced the expression of APP as well as GFAP mRNA levels in
the NT-2/D1 cells. (C) The data (means ± SD, n=3) presented are % changes of mRNA
expression of APP and GFAP compare to the control, NT-2/D1 cells only treated with 10
nM STS, as 100%.
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STS stimulate APP expression via ERK pathway
Although STS is known to be a PKC inhibitor 101, it is also reported to activate mitogenactivated protein kinase (MAPK) signal transduction 116, which is a major pathway
responsible for APP catabolism 117. Treatment of NT-2/D1 cells with 10 nM STS timedependently increased phosphorylation of ERK1/2 (p44/42 MAP kinases) after 45 min
of incubation (Figure 14 A). To further test the role of ERK signaling in STS-induced
APP expression, we pretreated NT-2/D1 cells with PD098059 118, a selective inhibitor of
MEK1 or SB203580 119, a selective inhibitor of p38 MAPK for 30 min prior to a 10nM
STS treatment with PD098059 or SB203580 for 24h. PD098059 inhibited STS-induced
APP (Figure 14 B) and GFAP (Figure 14 C) production at a concentration of 20µM or
greater, whereas SB203580 didn’t significantly alter APP and GFAP production.
Similarly, mRNA expression of APP also was inhibited by PD098059 at a concentration
of 20µM or greater (Figure 14 D and E). In addition, mRNA expression levels of GFAP
decreased according to the decrease of APP expression (Figure 14 D and E). These
results indicate that STS-induced APP and GFAP expressions are mediated by ERK1/2
signaling pathway not by p38 MAPK pathway and that STS-induced astrocytic
differentiation is mediated via ERK pathway by stimulating APP production.
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Figure 14: The involvement of ERK1/2 pathway in STS-induced astrocytic differentiation
of NT-2/D1. (A) NT-2/D1 cells were plated at a density of 1x106 cells and then treated
with 10 nM STS for indicated time period to induce astrocytic differentiation. Cell lysates
were subjected to immunoprecipitation with anti-human-pan-ERK Ab. Parallel blots
were probed with anti-phospho-p44/42 ERK Ab (P-ERK-1/2) and anti-pan-ERK Ab
(ERK-1/2). Phosphorylation of ERK1/2 increased progressively after 45 min. (B)
PD098059, a selective MEK1 inhibitor, decreased APP expression activated by 10 nM
STS in NT-2/D1 cells. While SB203580, a selective p38 MAPK inhibitor, did not affect
APP expression. (C) PD98059, decreased GFAP expression activated by 10 nM STS
in NT-2/D1 cells, while SB203580 did not affect GFAP expression. (D) PD98059,
decreased GFAP and APP gene expression activated by 10 nM STS in NT-2/D1 cells,
while SB203580 did not affect the gene expression. Gene expressions of APP and
GFAP were examined by RT-PCR in NT-2/D1 cells pretreated with various
concentrations of PD098059 or SB203580 for 30 min and exposed to 10 nM STS for 24
h. (E) Semi quantitative image analysis of gene expression data from (D). The data
(means ± SD, n=3) presented are % increase of mRNA expression of APP and GFAP
compare to the control as 100%.
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Discussion
NT-2/D1 cells have been thought to exclusively differentiate into pure neurons as a
neuronal progenitor. However, recent studies show astrocytic differentiation of NT-2/D1
cells by RA treatment 97, 99, indicating that it is a good in vitro model system for
analyzing regulation of neural differentiation. In the current study, we report that STS
induces astrocytic differentiation of NT-2/D1 by increasing APP expression via
activation of ERK1/2 signaling cascade.

Typical astrocytic stellate morphology appeared in the culture after 7 days of treatment
with STS and more than 90 % of cells showed this feature by week 2. These cells
expressed high levels of not only GFAP, a typical astrocyte marker but also astrocytespecific glutamate transporters such as GLAST/EAAT1 and GLT1-EAAT2, which are
used for removing excessive glutamate to maintain a physiological level of extracellular
glutamate concentration 120, indicating that STS differentiated NT-2/D1 cells into
astrocytes. Furthermore, STS treatment increased green fluorescent in NT-2/D1
transfected with reporter vector (pGFAP-GFP-S65T), indicating activation of GFAP
promoter by STS.

Apoptosis is closely associated with differentiation during development of the neuronal
system 121. Recent reports also show STS, a potent apoptosis inducer, causes early
neural stem cell like differentiation of embryonic stem cells 104. Although the mechanism
is not clear, STS is also reported to induce astrocytic phenotypes in C6 glial cells 106.
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Thus apoptotic cascade triggered by STS may be involved in the astrocytic
differentiation.

We found that APP expression, which is reported to be increased during apoptosis 122,
increased in NT-2/D1 cell culture after STS treatment. Although to date, most of APP
studies have been focused on neurotoxicity of Aβ, several lines of evidence suggest
that APP affects mechanisms of anti-apoptosis and neurite outgrowth 28, 111. Thus, the
increased expression levels of APP may be a compensation mechanism of the
apoptotic condition created by STS treatment. Down’s syndrome (DS) is associated with
a high incidence of AD with massive gliosis 123, 124. Recently Bahn et al. 56 demonstrated
that neurospheres derived from DS patients almost exclusively differentiated into GFAP
positive cells. Since DS patients have trisomy of chromosome 21, where the APP gene
is localized, we associate these incidents to an over expression of APP and speculate
that STS-induced APP expression might play a crucial role in glial differentiation of NT2/D1 cells.

In this study, knocking down APP expression of NT-2/D1 cells using RNA interference
(RNAi) against APP reduced GFAP expression induced by STS treatment. Although
STS may induce astrocytic differentiation of NT-2/D1 through various signaling
mechanisms, this result suggests that at least APP is involved in the induction of GFAP
expression during STS-induced glial differentiation.
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MEK1 inhibitor (PD098059), which reduces phosphorylation of ERK1/2, dosedependently reduced expression of APP and GFAP. Since APP expression is regulated
by phosphorylation of ERK1/2 125 and STS increases phosphorylation of ERK1/2 116,
STS may increase APP expression level by ERK1/2 phosphorylation. On the other hand
p38 MAP kinase inhibitor (SB203580) did not show any significant effect on APP and
GFAP expression. These results indicate that STS may induce GFAP expression
through the up regulation of APP by increasing ERK1/2 phosphorylation.

It is not clear how adult neurogenesis is essential for normal cognitive function in aging.
Although the rate of endogenous neuroregeneration in the adult brain may be minimal,
in the long run, pathologically-altered APP metabolism in AD or DS causes a defect in
neurogenesis and significantly harms normal brain function. This fact could also prevent
successful neuroreplacement therapy for AD using NSC by shifting the differentiation
pattern of the transplanted cells into glial cells rather than into neurons. Thus, in order
to use stem cell transplantation as a potential strategic intervention therapy for AD or
DC. Regulation of APP levels and/or modifications of the APP signal pathways within
the cells may need to be developed along with a better understanding of how the
mechanisms of APP function in neural stem cell biology.
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THE NOVEL FUNCTION OF AMYLOID PRECURSOR PROTEIN IN
GLIAL DIFFERENTIATION IS MEDIATED THROUGH IL-6/GP130
SIGNALING PATHWAY

Introduction
During neural development, neurons are typically differentiated before astrocytes and
oligodendrocytes with the exception of a few sites of postnatal and adult neurogenesis
such as the subventricular zone (SVZ) of the fore brain 126, 127. Current studies showed
that different kind of population of brain cells can be sequentially generated from
individual progenitors by cell intrinsic factors as well as extrinsic cues from surrounding
environment 128. Generally, glial differentiation is occurred during relatively late
embryonic stage (mouse E16-17 day) and the postnatal period by various factors 129. To
date, interleukin (IL-6) cytokine families 130, bone morphogenic factors (BMPs) 131, basic
fibroblast growth factor (bFGF) 132, and Notch signaling 133 has been known as an
important gliogenic factors, functioning only in E15 or more order cortical progenitors.
Although these gliogenic factors also exist in the earlier embryonic stage (around E1112), they promote proliferation of neural stem cells instead of glial differentiation by
various factors such as DNA methylation 53 and bHLH transcription factor (Neurogenin 1
or Neurogenin 2) 134.

IL-6-induced JAK/STAT signaling pathway is a central part of the glial differentiation
process 40. There are reported several IL-6 family cytokines such as leukemia inhibitory
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factor (LIF), CNTF, IL-6, and oncostatin M (OSM) 130. Once these IL-6 cytokine families
interact with their cognate receptors (ex, IL-6 receptor α), the resultant complexes are
then associated with gp130 44, crucial signal transducing component of IL-6 receptor.
Subsequently, formation of receptor heterodimers stimulates a downstream
transcription factor, signal transducer and activator of transcription (STAT) proteins by
activation of JAKs, especially JAK1 and JAK2. Predominantly, STAT3 molecules get
phosphorylation, and then the phosphorylated STAT3s form dimerization and undergo
translocation into the nucleus. Finally, STAT3 dimers bind to the putative STAT3 binding
element of GFAP promoter, typical astrocytic marker, for glial differentiation

Despite above-mentioned reports have intensively showed the mechanisms of glial
differentiation, there still remain other factors that induce differentiation by unknown
mechanisms. The APP is a membrane spanning glycoprotein consisting of a 695- to
770-amino acid 9. To date, the cytotoxicity of Aβ peptides, generated by subsequent
cleavage of β- and γ-secretase, has been focused due to its cytotoxicity in the brain,
leading to the pathophysiology of AD 135. Although several physiological function of APP
has been reported, it is still controversial and needs to be clarified 26. However,
crystallography studies showed that the structure of N-terminal domain of APP (23-128
a.a residues) is harboring growth factor-like structure which possesses three disulfide
bridges and cystein rich regions 27. Moreover, this domain include heparin binding site
which is usually positively charged basic region. Furthermore, several studies provided
evidence for the view that released sAPP may operate as a factor that is able to evoke
coordinated cellular response in specific target cells 85, 136, 137. For example, sAPP
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interacts with the class A scavenger receptor (SR-A), showing the physiological function
of sAPP as a ligand 54. In this receptor-ligand interaction, negatively charged N-terminal
domain of APP (191-264 a.a) was identified as an essential domain for physical
interaction with SR-A. Thus, these reports suggest secreted type of APP may regulate
cellular function via certain receptors.

On the other hand, several lines of reports showed the potential role of APP in the stem
cell biology. DS patients have 3 copies of chromosome 21138. Since APP coding gene is
also located in chromosome 21, DS patients express high level of APP and shows
similar symptoms of AD on their later stage 138, 139. Interestingly, while normal subjects’
neural stem cells were differentiated into neuron and glia with a half ratio, most of DS
patients’ neural stem cells were differentiated into astrocytes 56. Therefore, this indicates
that high concentration of soluble APP possibly affects cell fate specification of neural
stem cells of DS patient. Previously, we reported that treatment of high concentration of
sAPPα or overexpression of APP enhanced the glial differentiation of HNSCs 140.
Moreover, we also found that an important role of APP in staurosporine (STS)-induced
glial differentiation of neural progenitor, NT-2/D1 cells 141.

In the present study, we examined specific glial differentiation mechanism stimulated by
sAPP in NT-2/D1 cells. Then, we found that IL-6 cytokine signaling pathway is crucial
for the sAPP–induced glial differentiation. Therefore, these results implicate a deficiency
of stem cell biology by altered APP metabolism in AD pathology.
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Materials and methods

Reagents and antibodies
Jak2 inhibitor, AG490 (tyrphostin B42; Sigma) were dissolved in dimethyl sulfoxide and
stored at -80℃ until use. Recombinant sAPPα protein (Sigma) was solubilized with
dH2O and stored at -80°C until use. The following antibodies (Abs) were used: mouse βIII tubulin Ab (Sigma); rabbit anti-GFAP Ab (Promega); mouse anti-APP Ab (22C11)
(Chemicon); rabbit anti-human STAT3 Ab (Chemicon); rabbit anti-phospho-STAT3
(Tyr705) Ab (Cell Signaling); mouse anti-CD130 (gp130) Ab (Chemicon); anti-phosphotyr Ab (4G10) (Upstate) and rabbit anti-β-actin Ab (Cell Signaling). For the secondary
Abs, anti-mouse and anti-rabbit horseradish peroxidase-conjugated secondary Abs
(Jackson Immunoresearch Laboratory) were used.

Cell culture and transfection
The NT-2/D1 cells were seeded (5x106 cells per 150 mm petri dish) in Dulbecco’s
modified Eagle’s medium (DMEM/F-12; Invitrogen) supplemented with 10% heat
inactivated fetal bovine serum (FBS; Novacell), 1% antibiotic-antimycotic (Invitrogen), 4
mM glutamine (Invitrogen) and maintained in a humidified atmosphere of 5% CO2/95%
air at 37ºC 97, 142. The cells were passed twice a week by short exposure to 0.25%
trypsin/0.01% EDTA (Invitrogen). For the experiments, 1×106 NT-2/D1 cells were plated
in a 6 well tissue culture plate and subsequently, APP-induced differentiation of NT2/D1 cells was evaluated for expression of astrocytic and neuronal markers by RT-PCR
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and Western blot analysis under the treatment of recombinant sAPP. Transient
transfection of various siRNA PCR fragments (siJAK1, siSTAT3 and siCNTF), which
suppress the gene expression of JAK1, STAT3 and CNTF, respectively, were
performed with LipofectamineTM 2000 (Invitrogen) on subconfluent NT-2/D1 cells in a 6well culture plate, according to the manufacturer's protocol. Transfection efficiency was
determined by transfection of 0.5 µg of pEGFP-C1 (Clontech). Cells were rinsed twice in
ice-cold phosphate-buffered saline (PBS, pH7.4) after 48h of the incubation and mRNA
samples were extracted for further analysis.

RT-PCR analysis
Total RNA was extracted from the cells with Trizol reagent (Invitrogen) according to the
manufacturer’s protocol. One µg of the total RNA was reverse-transcribed and amplified
by the SuperScriptTM ONE-STEPTM RT-PCR system (Invitrogen) with the following
primers: IL-6R (+) 5′-CATTGCCATTGTTCTGAGGTTC-3′, (-) 5′AGTAGTCTGTATTGCTGATGTC-3′; gp130 (+) 5′-AAGGATGGTCCAGAATTCAC-3′, (-)
5′-CCTTCACTGAGGCATGTCGC-3′, (-); GFAP (+) 5’-AAGCAGTCTACCCACCTCAG3’, (-) 5’-ATCCCTCCCAGCACCTCATC-3’; CNTF (+) 5’CAGGGCCTGAACAAGAACAT-3’, (-) 5’-GCCAACAAAACATGGAAGGT-3’; LIF (+) 5’CTGTTGGTTCTGCACTGGA-3’, (-) 5’-GGGTTGAGGATCTTCTGGT-3’; JAK1 (+) 5’TGCTCCTGAGTGTGTTGAGG-3’, JAK1 (-) 5’-AGGTCAGCCAGCTCCTTACA-3’;
STAT3 (+) 5’-TTTCACTTGGGTGGAGAAGG-3’, STAT3 (-) 5’GCTACCTGGGTCAGCTTCAG-3’; β-actin (+) 5’-GACAGGATGCAGAAGGAGAT-3’, (-)
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5’-TTGCTGATCCACATCTGCTG-3’. Ten µl of the reaction were then separated on a
2% E-gel (Invitrogen).

Immunoprecipitation and western blot analysis
Protein samples were prepared by lysing the cells using an ice-cold lysis buffer consist
of 1% NP40, 150 mM NaCl, 50 mM Tris pH8.0 and Complete Protease Inhibitor Tablets
(Boehringer). The protein concentration of each sample was measured by Bio-Rad
protein assay (Bio-Rad). Lysates were immunoprecipitated with an antibody against
STAT3 and gp130 molecules using protein A-Sepharose (Amersham Bioscience).
Then, precipitates were heated at 70ºC for 10 min in LDS (Lithium Dodecyl Sulfate)
sample loading buffer (1×) and separated on NuPAGETM 4-12 % Bis-Tis Gel (Invitrogen)
for 45 min at 200 V and transferred to PVDF membrane (30V, 60 min). Membranes
were blocked with 5% skim milk in PBS for 1h at RT and probed at 4ºC overnight with
primary antibody in 5% skim milk. The membranes were washed 3 times for 5min each
with PBS containing 0.05% Tween 20 (pH7.4) and then incubated with horseradish
peroxidase-conjugated secondary antibodies in 5% skim milk for 2h at RT. After 3 times
washing with PBS containing 0.05% Tween 20, immunoreactive bands were visualized
by using ECL plus (Amersham Bioscience) chemiluminescence reagent.

siRNA preparation
Human STAT3 (Genbank access number: NM_003150), Jak1 (Genbank access
number: AB219242) and CNTF (Genbank access number: NM 000614) mRNA target
sequences were designed using ambion target finder software. The mRNA target
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sequences of human STAT3, Jak1 and CNTF were 5’-TATCATTGACCTTGTGAAA-3’
(1919-1938), 5’-CCACATAGCTGATCTGAAA-3’ (2710-2729) and 5’TACAAGATCCCCCGCAATG-3’ (475-494), respectively. siRNA PCR products were
synthesized using a SilencerTM Express kit (Ambion). Then, cells were transfected with
siRNAs and incubated for 48 hr. The silencing efficacy was confirmed by RT-PCR.

Immunocytochemistry
Detailed methods for immunocytochemistry were previously described 140. Briefly, for
HNSC staining, after fixation, samples were washed in phosphate-buffered saline with
0.2 % Triton X (PBST), then incubated in PBST containing appropriate normal sera.
Next, the samples were incubated overnight (up to 16 hr) with primary antibodies, and
then incubated with secondary antibodies for 1.5 hr in a dark humidified chamber after
washing with PBS. Next, the samples were washed thoroughly in PBS and coverslipped
with VECTASHIELD® DAPI Mounting Media (Vector).

Image analysis
Gel and Western blot images were captured by KODAK Image Station 2000MM
(KODAK). Optical density of the target bands were analyzed by ImageJ software (NIHIMAGE Version 4.1) and expressed in Mean±SD form experiments performed in
triplicates.
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Results

sAPP induces glial differentiation via IL-6 cytokine related signaling pathway
To investigate the physiological role of sAPP as a gliogenic factor, HNSCs were treated
with recombinant sAPPα (100ng/ml) and were differentiated under serum-free
unsupplemented conditions. HNSCs treated with sAPPα revealed a significantly higher
level of GFAP-positive cells compared to control HNSCs at 5DIV (Figure 15A). While
the HNSC controls were differentiated into neurons and glial with a relatively even ratio,
treatment of sAPPα induced massive glial differentiation of treated HNSCs. These
results indicate that an overdose of the wtAPP causes gliogenesis rather than
neurogenesis in vitro.

To investigate how sAPP induces glial differentiation of neural stem cells, first, we
examined the potential involvement of IL-6 cytokine related signaling pathway. As we
mentioned above, Santiago-Garcia et al. reported the novel function of APP as a ligand
for the SR-A of macrophages 54. Concurrently, the structural property of N-terminal
domain of sAPP also indicated that secreted soluble APP may have a growth factor like
function which interacts with cell surface receptor27. Thus, we hypothesized that
released sAPP may stimulate IL-6 cytokine related signaling pathway, similar to other
IL-6 ligand such as LIF, CNTF and etc. To verify whether sAPP activates IL-6/gp130
signaling, we examined the gene expression of various molecules related with IL-6
cytokine families, such as IL-6R, gp130, CNTF, LIF, JAK1, and STAT3, in the presence
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of sAPP (Figure 15B). Consistently with immunohistochemistry data, the treatment of
sAPP promoted expression of GFAP, a typical astrocyte marker 113. While IL-6 R and
LIF gene expression level was not changed, expression level of gp130 and CNTF was
substantially increased by treatment of sAPP. Among downstream signaling molecules,
although expression of STAT3 does not show any significant changes in mRNA level,
expression level of JAK1 was increased by treatment of sAPP. In general, various IL-6
cytokine families have induced different cellular response by stimulating certain
‘preferred’ molecules from IL-6 receptors, JAKs, and STAT molecules 143. In this context,
our results suggest that sAPP induces glial differentiation of NT-2/D1 cells through IL-6
signaling cascade by specific upregulation of expressions of gp130, CNTF and JAK1.
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Figure 15: Differentiation of HNSCs and IL-6/gp130 related gene expressions were
altered by high concentration of sAPP. (A) APP transfection increases the glial
population of HNSCs in vitro. Double immunofluorescence staining with GFAP (red) and
βIII-tubulin (green) markers for astrocytes and neurons, respectively. All nuclei are
counterstained with DAPI (blue). HNSCs transfected with mammalian expression
vectors containing genes for wild-type APP (wtAPP) differentiated under serum-free
unsupplemented conditions displayed a significantly reduced level of neural
differentiation (a) compared with HNSCs transfected with the vector alone at 5DIV (b).
The abnormal morphology of the processes is shown in neuronally differentiated
HNSCs (green) with wtAPP gene transfection (a). (B) sAPP–induced gene expression
changes, which are related with IL-6 signaling cascade, were assessed by RT-PCR.
Recombinant protein sAPP (100ng/ml) was applied to NT-2/D1 cells for 2 hr, then,
mRNAs were extracted for RT-PCR analysis.
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sAPP affects expression and phosphorylation of gp130 during glial differentiation
For further investigation, we examined critical changes of the IL-6/gp130 signaling
cascade related molecules from upstream signaling pathway. Since expression of
gp130 was significantly promoted by sAPP, we examined the functional importance of
gp130, which is known as a signaling subunit of IL-6 receptor, in the presence of sAPP
by measuring expression and phosphorylation of gp130 (Figure 16A) 144.

When lL-6 cytokine families interact with non-signal transducing receptors (ex, IL-6Rα
and LIF-Rα), those receptor/ligand complexes came to interact with gp130. Then, those
complexes are phosphorylated by JAKs and subsequent phosphorylation events are
occurred. Treatment of sAPP induced slight increase of gp130 expression from 15 min.
sAPP-induced gp130 expression reached its highest level at 60 min after treatment,
then slightly decreased at 120 min. As mentioned above, interaction of gp130 with IL-6
cytokines induces conformational changes and recruit various tyrosine kinases, for
instance, JAKs (JAK1, JAK2, JAK3, and TYK2) and tyrosine phosphatase such as an
SH2 domain containing protein tyrosine phosphatase (SHP-2) (Figure 16B). We thus
examined phosphorylation level of gp130 after treatment of sAPP. As shown in Fig. 16B,
treatment of sAPP induced early on-set of tyrosine phosphorylation of gp130. Treatment
of sAPP induced phosphorylation of gp130 in early on-set (15 min) and later on it was
undetectable until 45min. However, phosphorylation of gp130 was come back to basal
level from 60 min again 145. Subsequently, phosphorylated gp130 may recruit
downstream signaling molecules such as JAK/STAT to send signals to downstream.
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Since expression and phosphorylation of gp130 was immediately changed by treatment
of sAPP, we postulated that sAPP may directly interact with gp130 receptor subunit,
similar with other ligands. To examine interaction between APP and gp130, we did an
immunoprecipitation with anti-gp130 antibody and blotted with anti-22C11 antibody.
Then, our result indicates that sAPP can stimulate IL-6/gp130 signaling cascade by
direct interaction with gp130 receptor (Figure 16C).

In Figure 16D and E, we applied anti-gp130 (CD130) Ab to block the effect of sAPP on
IL-6/gp130 signaling pathway since anti-gp130 Ab interferes correct formation of
ligand/receptor complexes 146. Then, GFAP expression and phosphorylation level of
STAT3 was assessed. Treatment of anti-gp130 Ab successfully downregulated GFAP
expression as well as STAT3 phosphorylation in the presence of sAPP (Fig. 16D and E).
These results suggest that signals, stimulated by sAPP, are transduced via gp130 for
glial differentiation of neural progenitor NT-2/D1 cells.
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Figure 16: sAPP induces glial differentiation by upregulating expression and
phosphorylation of gp130 in neural progenitor, NT-2/D1 cells. sAPP induced gp130
expression was measured by western blot using anti-gp130 Ab in a various time frame
(0-15-30-45-60-120 min). (B) sAPP induced phosphorylation of gp130 was assessed by
co-immunoprecipitation. Protein extracts from sAPP treated NT-2/D1 cells were
immunoprecipitated with anti-gp130 Ab. Then, membranes were probed with anti-p-Tyr
(4G10) Ab. NT-2/D1 cells were treated with sAPP for 16 hr in the presence/absence of
the anti-gp130 blocking Ab and the expression changes of GFAP (C) and
phosphorylation of STAT3 were examined (D) by western blot analysis.
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sAPP induced glial differentiation is mediated via intracellular mediators of IL-6
signaling pathway
It has been previously documented that phosphorylation of downstream signaling
molecules of gp130, such as JAKs and STAT3, are observed after stimulation of the IL6 family of cytokines 130. Although gene expression level of STAT3 wasn’t changed, the
importance of STAT3 shouldn’t be underestimated since phosphorylation status is also
crucial for the function of STAT3 in glial differentiation (Figure 15B) 147. We thus
examined whether treatment of sAPP induces phosphorylation events in STAT3. When
100ng/ml of sAPP was applied into NT-2/D1 cells, it promoted phosphorylation of
STAT3-p-Tyr705 residues from 30 min after sAPP treatment with time-dependent
manner (Figure 17A) 145.

Recently small interference RNA (siRNA) has been intensively used as a tool for
studying the function of gene of the interest 148. Here, we constructed siRNA PCR
products against JAK1 and STAT3 to verify the role of those molecules in sAPPinduced gliogenesis. These siRNA PCR products showed successful silencing efficacy
on expression of JAK1 and STAT3 (Figure 17B). When these siRNA PCR products
were transfected into NT-2/D1 cells, the application of siRNA downregulated GFAP
expression by knocking down JAK1 and STAT3 expression even under the treatment of
sAPP (Figure 17C). Therefore, those results suggest that sAPP-induced glial
differentiation is mediated by JAK/STAT in IL-6/gp130 signaling pathway.
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On the other hand, we also examined the function of JAKs in sAPP-induced glial
differentiation mechanism by inhibiting JAKs using selective inhibitor (AG490;
Tyrphostin B42) as well as siRNA. Since phosphorylation of STAT3 at Tyr-705 residues
are catalyzed by the JAKs (JAK1, JAK2, JAK3, and TYK2), we hypothesized that the
application of JAK inhibitor might suppress phosphorylation of STAT3 molecules as well
as GFAP expression. As demonstrated in Figure 17C, the transfection of siRNA of JAK1
efficiently knocked-down gene expression of GFAP under the presence of sAPP.
Furthermore, as shown in Figure 18A and B, treatment of AG490 suppressed GFAP
expression as well as phosphorylation of STAT3-p-Tyr705 149. Taken together, these
results indicate that sAPP–induced gliogenesis is mediated by IL-6/gp130 signaling
pathway through gp130 and downstream signaling molecules, JAKs and STAT3.
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Figure 17: sAPP-induced glial differentiation is mediated by STAT3 in IL-6/gp130
signaling pathway. (A) Phosphorylation of STAT3 was analyzed by western blot. For
immunoprecipitating STAT3 molecules, protein extracts from sAPP treated NT-2/D1
cells were applied with anti-STAT3 Ab. Then, phosphorylation of STAT3 molecules
were assessed by probing with anti-STAT3-P705. Phosphorylation of STAT3 was also
assessed in a various time frame (0-15-30-45-60-120 min). (B) Efficacy of siRNA
targeting on JAK1 and STAT3 were assessed. NT-2/D1 cells were transfected with
siRNAs of JAK1 and STAT3 and grown for 2 days. Then, sAPP were treated for 16 hr.
To measure the efficacy of siRNA, RT-PCR was performed using JAK1 and STAT3
recognizing primers. (C) NT-2/D1 cells were transiently transfected with siRNA targeted
to JAK1 and STAT3 for 2days and then incubated the cells for 16 hr with sAPP. Total
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RNAs were analyzed for expression of GFAP. Expression of ββ-actin was examined as
a loading control.
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Figure 18: sAPP-induced glial differentiation is mediated by JAKs in IL-6/gp130
signaling pathway. JAK2 was also involved in sAPP induced astrocytic differentiation via
IL-6 signaling pathway. To inhibit the function of JAK2, NT-2/D1 cells were preincubated
with JAK2 inhibitor, AG490, for 1 hr. Subsequently, 100ng/ml of sAPP was treated into
NT-2/D1 cells for 16 hr. To investigate the function of JAK2 in sAPP-induced glial
differentiation, western blot analysis was performed to detect GFAP expression and
STAT3 phosphorylation. Then, Treatment of AG490 suppressed STAT3
phosphorylation (A) as well as expression of GFAP with dose-dependent manner (B).
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sAPP-induced CNTF expression is important for glial differentiation
CNTF is one of the IL-6 cytokine family extrinsic factors which are associated with glial
differentiation of neural stem cells. Upregulation of CNTF expression was observed in a
short-term (2 hr, Fig 15B) as well as long-term treatment (1-2-3-4-5 day, Figure 19A) of
sAPP. This result suggests that sAPP-induced glial differentiation is potentiated by the
increase of CNTF expression in NT-2/D1 cells. Although it is still not known how sAPP
enhances CNTF expression, based on recent reports, upregulation of CNTF is triggered
by the positive autoregulatory mechanism. To investigate function of CNTF in the
context of s APP-induced glial differentiation, we also constructed and transfected
siRNA, specifically silencing CNTF expression, into NT-2/D1 cells (Figure 19B). Then,
versatile siRNA of CNTF suppressed GFAP expression level with dose-dependent
manner in the presence of sAPP. Although still further studies are needed, this result
indicates that s APP might stimulate IL-6/gp130 signaling pathway by promoting CNTF
expression.
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Figure 19: sAPP induces glial differentiation via upregulation of CNTF expression. (A)
sAPP–induced CNTF gene expression changes were assessed by RT-PCR. 100ng/ml
of sAPP was applied to NT-2/D1 cells for 0-1-2-3-4-5 days, then, mRNAs were
extracted for RT-PCR. Expression of β-actin was examined as a loading control. (B) To
elucidate the function of CNTF, siRNA of CNTF and non-specific siRNA was generated
and transiently transfected into NT-2/D1 cells for 2 days and then cells were incubated
for 16 hr with sAPP. Total RNAs were analyzed for expression of GFAP. Expression of
β-actin was examined as a loading control.
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Discussion
Glial differentiation is occurred at relatively later stage (E16, 17 or perinatal stage) of the
development of the mammalian CNS. During this stage, glial differentiation of the neural
stem cell is tightly modulated by various extrinsic (ex, LIF, CNTF, Notch, and BMPs)
and intrinsic factors (ex, Ngn1, Ngn2, and DNA methylation). Extensive current studies
have revealed that IL-6/gp130 signaling pathway is the central part of the glial
differentiation of neural stem cells. When ligands, such as LIF and CNTF, bind to
receptor, subsequent phosphorylation of gp130, JAK and STAT3 are occurred. Then,
phosphorylated STAT3 complexes translocate into the nucleus and stimulate target
gene expression by interacting with STAT3 binding element of the target gene such as
GFAP. Interestingly, IL-6/gp130 signaling pathway is efficiently modulated by
autoregulatory loop to coordinate with other part of the glial differentiation machinery
such as Notch, and BMPs.

Although APP has been intensively studied due to the cytotoxicity of the Aβ peptides in
the brain, we have reported novel function of sAPP as a gliogenic factor in stem cell
differentiation. In our previous studies, higher concentration of sAPP induced massive
glial differentiation of HNSCs under the condition of basal media differentiation. Since
basal media doesn’t contain serum, we can rule out the effect of any other growth
factors and trophic factors 79. Thus, this result suggests that the unique function of sAPP
as a gliogenic factor in the HNSCs. Furthermore, in our previous studies, we
investigated the function of sAPP in the glial differentiation, induced by STS 104. Despite
STS has been used as a PKC inhibitor or apoptosis inducing reagent, recently, it also
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showed the novel function as a terminal differentiation reagent. Under the treatment of
STS, neural progenitor NT-2/D1 cells were differentiated into glia, showing GFAP
expression as well as astrocyte-specific morphological changes. Concurrently,
expression level of APP was also upregulated by the treatment of STS by stimulating
ERK signaling cascade whereas the application of siRNA of APP efficiently silenced
expression of GFAP even in the presence of STS. Although our finding suggests that
APP has a crucial correlation with GFAP expression during the glial differentiation,
further studies are still needed to clarify the specific mechanisms, implicated in the
promotion of glial differentiation. To answer that question, we investigated whether
treatment of sAPP activates major glial differentiation mechanism such as IL-6/gp130
signaling pathway.

In the present study, we found that the novel function of sAPP as a gliogenic factor in
neural progenitor, NT-2/D1, cells. Treatment of sAPP (100ng/ml) induced massive glial
differentiation of HNSCs while untreated HNSCs were differentiated into neuron and glia
evenly, showing consistent with our previous reports (Figure 21A). To elucidate whether
IL-6/gp130 signaling pathway is crucial for sAPP-induced glial differentiation, we
examined gene expression pattern of IL-6 relevant genes such as IL-6R, gp130, CNTF,
LIF, JAK1, STAT3, and GFAP under the treatment of sAPP (Figure 15B). Since different
kind of the IL-6 cytokine subfamilies induce distinct patterns of expression and
phosphorylation status of signaling molecules involved in IL-6/gp130 signaling pathway,
probably, IL-6/gp130 signaling may respond distinctively to treatment of sAPP

143

. In

our experimental condition, treatment of sAPP enhanced expression of gp130, CNTF,
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JAK1 and GFAP. Therefore, there results suggest that IL-6/gp130 signaling pathway is
stimulated by treatment of sAPP.

Next, we examined the expression and phosphorylation status of gp130, signaling
subunit of IL-6 receptor, in the presence of sAPP (Figure 16A and B). The expression of
gp130 was gradually increased by sAPP up to 60 min and slightly downregulated at 120
min (Figure 16A). Treatment of sAPP also caused massive phosphorylation of gp130 in
the relatively early stage (15 min). The phosphorylation of gp130 was disappeared
quickly and then, came back to basal level at the later stage (60, 120 min) 145. The
gp130, in general, is phosphorylated by JAKs in the early stage of signal transduction.
The ligand/gp130 complex is rapidly dephosphorylated by the various phosphatases (ex,
SOCSs and SHPs) and internalized into the cytoplasm145. Therefore, our finding
suggests that upregulation of gp130 expression may be a compensatory mechanism to
maintain homeostasis of gp130 expression level.

Although sAPP could activate IL-6/gp130 signaling via upregulation of gp130, CNTF,
JAK1, increase of those gene expressions does not explain immediate phosphorylation
(< 15min) of gp130. Thus, we hypothesized that sAPP may directly activate IL-6/gp130
signaling cascade by physical interaction with gp130, similar to other IL-6 ligands. Our
immunoprecipitation result indicates that sAPP could directly interact with gp130.
Inversely, the application anti-gp130 Ab, which recognizes a ligand binding domain of
gp130 receptor 150, potently suppressed downstream signal transduction, such as
STAT3 phosphorylation and GFAP expression, by blocking the effect of sAPP on gp130
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receptors. Therefore, gp130 is a critical component in the sAPP-induced glial
differentiation for the transduction of outside signals, generated by sAPP.

JAK/STAT pathway has been extensively studied due to its regulatory role in various
biological systems such as an immune system and developmental biology. Especially,
JAK/STAT signaling pathway is a crucial system, implicated in astrocytic marker GFAP
expression, in glial differentiation process. In the present studies, treatment of sAPP
enhanced phosphorylation of STAT3-p-Tyr705 with time-dependent manner (Figure
17A). For suppression of the function of STAT3, siRNA of STAT3 PCR products was
transfected into NT-2/D1 cells (Figure 17B, C). GFAP expression, triggered by sAPP,
was drastically suppressed by the siRNA of STAT3.

On the other hand, we examined the involvement of JAKs in sAPP-induced glial
differentiation. The conformational change of gp130 recruits non-receptor kinases such
as JAKs. Subsequently, activated JAKs phosphorylate STAT3 molecules to form STAT3
homodimer complexes. Then, these STAT3 complexes are translocated into nucleus
and transactivate GFAP expression. When we transfected siRNA of JAK1 (Figure 17C)
and treated chemical JAK2 inhibitor, AG490 (Figure 18A, B), it efficiently suppressed
STAT3 phosphorylation as well as GFAP expression. These results indicate that
JAK/STAT is a crucial intracellular mediator of the s APP-induced glial differentiation of
NT-2/D1 cells.
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Next, we investigated how sAPP stimulates IL-6/gp130 signaling cascade for induction
of glial differentiation. Treatment of sAPP induced expression of CNTF, one of the
important extrinsic gliogenic factor, in an early on-set of gliogenesis (< 120 min) (Figure
15B) as well as in the longer period (up to 5 days) (Figure 19A). To elucidate the
function of CNTF in sAPP-induced glial differentiation, we generated and transfected
siRNA of CNTF (Figure 19B). Silencing CNTF expression potently suppressed GFAP
expression levels in the presence of sAPP. Though still further studies are necessary,
we thus postulated that treatment of sAPP may also promote glial differentiation by
upregulating CNTF expression in NT2-D1 cells.

Taken together, treatment of sAPP may activate IL-6/gp130 signaling pathway by direct
protein-protein interaction with gp130 and/or increase of CNTF expression. Then, serial
phosphorylation events are occurred in gp130, JAKs, and STAT3 molecules for the
signal transduction, triggered by sAPP. Moreover, expression of gp130 and JAK1 may
be promoted by the positive autoregulatory loop of the IL-6/gp130 signaling pathway to
strength glial differentiation process.

Our present results address us to novel paradigm in understanding of the
pathophysiological mechanism associated with DS or AD. While Aβ has been a
hallmark due to its clinical significance in AD, we showed the gliogenic function of sAPP
may be also a crucial factor, inducing glial differentiation of neural stem cell in AD
patient brain. Since the collections of neural progenitor population is still resided and
compensate the damaged cells in the brain, in a younger age, function of brain might be
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maintained normally by replacing defected cells with neurally differentiated endogenous
stem cells even under the high concentration of APP. However, in an aged brain,
decreased population of neural stem cells is not sufficient for replacing defected cells
under high-dose sAPP because sAPP-induced gliogenesis of neural stem cells
overwhelm neural differentiation. In the present studies, we found that massive glial
differentiation, caused by sAPP, may degrade the function of brain in AD or DS.
Although further studies are necessary, regulating environmental APP level would
provide better strategies for AD or DS by improving neurogenesis of endogenous neural
stem cells.
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THE NOVEL FUNCTION OF AMYLOID PRECURSOR PROTEIN IN
GLIAL DIFFERENTIATION IS ASSOCIATED WITH NOTCH SIGNALING
PATHWAY

Introduction
The amyloid precursor protein (APP) is a membrane spanning glycoprotein consisting of
695- to 770-amino acids 9. To date, the cytotoxicity of Aβ peptides, which are generated
by subsequent β- and γ-secretases cleavage of APP, has been extensively studied to
understand the pathophysiology of Alzheimer’s disease (AD) 9, 135, 151, 152. Despite the
wealth of studies regarding the physiological function(s) of APP, there is no consensus
on its physiological function 26. Thus, the physiological function(s) of APP remains to be
elucidated. A function of APP has been suggested as a ligand for receptors, such as the
class A scavenger receptor 54. Since crystal structure of the heparin-binding N-terminal
domain of APP resembles a growth-factor like domain 27, 30, 153, N-terminal soluble APP
(sAPP) may act as a growth factor. In our previous studies, we found that treatment with
α cleaved sAPP or over-expression of APP induced glial differentiation in a human
neural stem cells (HNSCs) culture 140. We also found that APP plays a critical role in
staurosporine (STS)-induced glial differentiation of NT-2/D1 cells 141. Interestingly, Bhan
et al. showed that NSCs isolated from Down’s Syndrome (DS) patients, who display AD
like pathology later in their life, differentiated into mainly astrocytes while NSCs from
healthy subjects produced both neurons and astrocytes 56. Since DS patients have
trisomy of chromosome 21, which contains gene coding APP, high levels of APP
expression in DS patients may responsible for the abnormal differentiation pattern of
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NSCs as well as the AD pathology found in DS 139, 154-156. Taken together, these findings
suggest that APP may involved in glial differentiation of NSCs.

Glial differentiation of NSCs is induced by various factors during the relatively late
embryonic stage (mouse E16-17) and postnatal period 39, 157, 158. These factors include
IL-6 cytokine families 130, 159, bone morphogenic factors (BMPs) 160, basic fibroblast
growth factor (bFGF) 52, and Notch ligands 161, 162. Notch signaling has been shown to
control cell fate through local cell to cell interactions. During development, Notch
suppresses neuronal differentiation in vivo and in vitro 47, 48. When ligands bind to
Notch, proteolytic cleavage of Notch receptors is occurred by γ-secretase/nicastrin
complex to release the signal-transducing Notch intracellular domain (NICD) 163.
Proteolytically cleaved NICDs translocate into the nucleus and interact with the nuclear
protein, referred to as CBF1/Su(H)/Lag-1 (CSL) 46. The CSL and NICD complex
activates the expression of primary target genes of Notch, such as Hairy and enhancer
of split (Hes) gene families 164. Following activation, Hes suppresses the expression of
transcription factors which are involved in neuronal differentiation such as Mash1 and
NeuroD. On the other hand, glial differentiation is strengthened by cross-talking
between IL-6 and Notch signaling pathways. IL-6 signaling pathway has been known as
a central part of gliogenesis. Subsequent phosphorylation of gp130, Janus kinases
(JAKs), and signal transducer and activator of transcription 3 (STAT3) induces glial
differentiation of neural stem cells. Interestingly, current study reported that glial
differentiation is potentiated by interacting with Hes1 and JAK2 because these protein
complexes facilitate accessibility of STAT3 to DNA binding element of GFAP promoter.
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In the present study, we demonstrate that sAPP may be a novel extrinsic factor that
induces glial differentiation of neural progenitor cells through the Notch signaling
pathway.

Materials and methods

Reagents and antibodies
The γ-secretase inhibitor, L-685,458 (Sigma), was dissolved in dimethyl sulfoxide and
stored at -80°C until use 165. Recombinant sAPPα protein (Sigma) was dissolved in
purified water and stored at -80°C until use. The following antibodies (Abs) were used:
rabbit anti-GFAP Ab (Promega); goat anti human-glial filament protein, GFAP (Nterminal human affinity purified, 1:400, Research Diagnostics Inc., Flander, NJ); mouse
anti human - amyloid beta antibody, 4G8 (1:50, Senetek); mouse IgG1 6E10, (1:50,
Senetek); mouse IgG anti-Alzheimer Precursor Protein A4, 22C11 (1:100, Chemicon);
mouse IgG2b anti-human βIII-Tubulin, clone SDL3D10 (1:1000, Sigma); Sheep anti
Bromodeoxyuridine (BrdU) (1:300, Sigma for detection of cells derived from
transplanted HNSCs); rabbit anti-human STAT3 Ab (Chemicon); mouse anti-phosphoSTAT3 (Ser727) Ab (Chemicon); rabbit anti-phospho-STAT3 (Tyr705) Ab (Cell
Signaling); rabbit anti-activated Notch Ab (Abchem); mouse anti-GFP Ab (Zymed); and
rabbit anti-β-actin Ab (Cell Signaling); anti-mouse IgG and anti-rabbit IgG horseradish
peroxidase-conjugated Abs (Jackson Immunoresearch Laboratory); anti-mouse, anti
goat, anti-sheep (1:500) conjugated with fluorescein (FITC) or rhodamine (TRITC)
(Jackson IR Laboratories, Inc.).
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Cell culture and transfection
NT2/D1 cells 142 were seeded at a density of 5x106 cells per 150 mm petri dish in
Dulbecco’s modified Eagle’s medium (DMEM/F-12; Invitrogen) supplemented with 10%
heat inactivated fetal bovine serum (FBS; Novacell), 1% antibiotic-antimycotic mixture
(Invitrogen), 4 mM glutamine (Invitrogen) and maintained in a humidified atmosphere of
5% CO2/95% air at 37ºC97. The cells were passed twice a week by short exposure to
0.25% trypsin/0.1% EDTA (Invitrogen). For all experiments, 1×106 NT-2/D1 cells were
plated in a 6-well cell culture plate and subsequently, APP-induced differentiation of NT2/D1 cells was evaluated for the expression of astrocytic and neuronal markers by RTPCR and Western blot analysis under the treatment of condition media or various
concentrations of recombinant APP.

Transient transfections were performed with vector constructs for pCDNA3.1; pCEPAPP695 (residues 1-695); pCMVIg-APP.1 (residues 1-678), pCMVIg-APP.2 (residues
1-205), [pCMVIg-APP.1 and pCMVIg-APP.2 (generously provided by Dr. Thomas
Suhduf (University of Texas Southwestern, USA)166]; pBOS-ZEDN1 (a kind gift from Dr.
Gerry

Weinmaster,

UCLA,

USA)).

All

transfections

were

performed

with

LipofectamineTM 2000 (Invitrogen) on sub confluent NT-2/D1 cells in a 6-well culture
plate according to the manufacturer's protocol. Cells were rinsed twice in ice-cold
phosphate-buffered saline (PBS, pH7.4) and 48h after the transfections, mRNA
samples were extracted for further analysis.
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Construction of pGFAP-GFP-S65T stable transfectant
NT-2/D1 cells were transfected with pGFAP-GFP-S65T (provided by Dr. Albee Messing,
University of Wisconsin-Madison) using LipofectamineTM 2000 (Invitrogen) 167. After
selection with 400µg/ml geneticin, G418 (Invitrogen) for 15-20 days, single colonies
were picked and tested for reporter assay. The pGFAP-GFP-S65T stably transfected
cells were cultured in DMEM/F-12 supplemented with 10% heat inactivated FBS, 1%
antibiotic-antimycotic, 4 mM glutamine and 200µg/ml G418.

RT-PCR analysis
Total RNA was extracted from the cells with Trizol reagent (Invitrogen) according to the
manufacturer’s protocol. One µg of the total RNA was reverse-transcribed and amplified
by the SuperScriptTM ONE-STEPTM RT-PCR system (Invitrogen) with the following
primers: GFAP (+) 5’-AAGCAGTCTACCCACCTCAG-3’, (-) 5’ATCCCTCCCAGCACCTCATC-3’; Delta1 (+) 5’-TGCTGGGCGTCGACTCCTTCAGT-3’,
(-) 5’-GCCTGGCTCGCGGATACACTCGTCACA-3’; Jagged-1 (+) 5’ACACACCTGAAGGGGTGCGGTATA-3’, (-) 5’-AGGGCTGCAGTCATTGGTATTCTGA3’; Hes1 (+) 5’-CGGACATTCTGGAAATGACA-3’, (-) 5’-CATTGATCTGGGTCATGCAG3’; hNotch1 (+) 5’-GATGCCAACATCCAGGACAACATGGG-3’, hNotch1 (-) 5’GGCAGGCGGTCCATATGATCCGTGAT-3’; hNotch2 (+) 5’ACATCATCACAGACTTGGTC-3’, hNotch2 (-) 5’-CATTATTGACAGCAGCTGCC-3’;
EGFP (+) 5’-CAAGGACGACGGCAACTACAAGAC-3’, (-) 5’GCGGACTGGGTGCTCAGGTAGTGGT-3’; β-actin (+) 5’92

GACAGGATGCAGAAGGAGAT-3’, (-) 5’-TTGCTGATCCACATCTGCTG-3’. Ten µl of
the reaction mixtures were then analyzed on a 2% E-gel (Invitrogen). Gel images were
captured using a KODAK Image Station 2000MM (KODAK).

Immunoprecipitation and western blot analysis
Protein samples were prepared by lysing the cells with ice-cold lysis buffer consisting of
1% NP40, 150 mM NaCl, 50 mM Tris pH8.0 and Complete Protease Inhibitor Tablets
(Boehringer). The protein concentration of each sample was measured by Bio-Rad
protein assay (Bio-Rad). Lysates were immunoprecipitated with antibodies against
GFAP, STAT3 and NICD molecules using protein A-Sepharose (Amersham
Bioscience). Following immunoprecipitation, the samples Then immunoprecipitants or
cell lysates were heated at 70ºC for 10 min in LDS (Lithium Dodecyl Sulfate) sample
loading buffer (1×) and separated on NuPAGETM 4-12 % Bis-Tis Gel (Invitrogen) for 45
min at 200 V and transferred to a PVDF membrane (30V, 60 min). Membranes were
blocked with 5% skim milk in PBS for 1h at RT and probed at 4ºC overnight with primary
antibody in 5% skim milk. The membranes were washed 3 times for 5min each with
PBS containing 0.05% Tween 20 (PBS-T, pH7.4) and incubated with horseradish
peroxidase-conjugated secondary antibodies in 5% skim milk for 2h at RT. After 3 times
washing with PBS-T, immunoreactive bands were visualized by using ECL plus
(Amersham Bioscience) chemiluminescence reagent. Western blot images were
captured with KODAK Image Station 2000 MM (KODAK).
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Stereotactic injection of HNSCs into mice
8 months old male APP23 transgenic 168, and wild-type mice were deeply anesthetized
with a 1:1 mixture of Ketamine (100 mg/kg) and Xylazine (20 mg/kg) and mounted onto
a stereotaxic apparatus (ASI Instrument, USA). Using bregma as a reference point,
approximately 105 cells HNSCs were suspended in 10 µl PBS, and slowly injected into
the right lateral ventricle (coordinates: anterior posterior (A/P)–0.6 mm; medial lateral
(M/L) +1.0 mm; dorsal/ventral (D/V) +2.4 mm) of each mouse using a 25 µl Hamilton
gastight syringe (Hamilton, Reno, NV, USA) attached with a 22-gauge beveled needle.

Immunohistochemistry
Detailed methods for immunohistochemistry have previously been described 67, 169.
Briefly, 6 weeks post-transplantation, animals were sacrificed by an overdose of a 1:1
mixture of Ketamine (100 mg/kg) and Xylazine (20 mg/kg), and a subgroup of animals
(n=6-8) were transcardially perfused with phosphate buffer (PBS). Brains were
removed, dissected into the hippocampus and cortex, and tissue samples were
maintained on dry ice and stored at -80° C until Western blotting experiments were
performed. The remaining group of mice with HNSC implants (n=6) were transcardially
perfused with PBS and 4% paraformaldehyde (pH 7.4). Brains were removed and postfixed for 8-12 h in 4% paraformaldehyde, and cryoprotected in 20% sucrose-PBS
overnight. The brains were subsequently cut on a cryostat (20 µm coronal free floating
sections) and kept in PBS at 4° C. For fluorescent immunohistochemical analysis,
sections were washed three times and blocked with 3% donkey serum in PBS
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containing 0.25 %Triton X-100 for 1 hr at RT. After serum blocking, sections were
incubated with a combination of primary antibodies, diluted in PBS containing 0.25%
Triton X-100 and with 3% normal donkey serum overnight at 4°C. After 3 washes in
PBS-T, sections were incubated with corresponding secondary antibodies for 2 hr at
RT. After a final wash in PBS-T, sections were mounted and cover slipped with
Vectashield with DAPI (Vector Laboratories, Inc., Burlingame, CA) and observed using
a Leica DMRB fluorescent microscope. Microscopic images were taken with an
Axiocam digital camera (Carl Zeiss) mounted on the DMRB and processed using the
QIMAGING with Q Capture software (Qimaging Corporation).

Immunocytochemistry
For fluorescent immunocytochemistry of the HNSCs, Treatment of recombinant sAPPα
and transfection of APP expression vector was performed. Cells were fixed in 4%
paraformaldehyde for 20 min at RT, and then washed in PBS-T, and thereafter
incubated in PBS-T containing 3 % normal donkey serum. Next, the samples were
incubated overnight at 4(up to 12 hr) with the following primary antibodies mouse anti
human - amyloid beta antibody, 4G8 (1:50, Senetek); mouse IgG1 6E10,
(1:50,Senetek); mouse IgG anti-Alzheimer Precursor Protein A4, 22C11 (1:100,
Chemicon); mouse IgG2b anti-human βIII-Tubulin, clone SDL3D10 (1:1000, Sigma) and
goat anti human-glial filament protein, GFAP (N-terminal human affinity purified, 1:400,
Research Diagnostics Inc., Flander, NJ). After washing with PBS, samples were
incubated with corresponding secondary antibodies coupled to FITC or TRITC for 1.5 hr
in a dark humidified chamber. Next, the samples were washed thoroughly in PBS and
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cover slipped with Vectashield mounting media with DAPI (Vector) for fluorescent
microscopic observation.

Results

Increased glial differentiation of HNSCs in APP23 transgenic mice
To examine whether APP has an effect on the differentiation of HNSCs in adult mice in
vivo, we transplanted HNSCs into the cerebro lateral ventricle of APP23 transgenic and
wild type (WT) mice at 8 and 12 months of age. To identify the transplanted HNSCs in
the host brain, anti-human specific GFAP antibody was used for the fluorescent
immunohistochemistry. Majority of the transplanted HNSCs differentiated into GFAPpositive astrocytes in the cortex of APP23 transgenic mice 4weeks after transplantation
while less GFAP-positive cells were found in the WT mice (Figure 20A-a and b). In 12
month old APP23 mice with progressed Aβ pathology, more activated astrocytes were
found surrounding the area of Aβ deposits (Figure 20A-c). These results indicate that
high level of APP in the transgenic mouse induces glial differentiation of HNSCs and Aβ
deposits may attract and/or activate astrocytes. We compared the protein expression
levels of APP, GFAP and NICD in the cerebral cortex of 8 month WT and APP23 mice
using Western blot analysis (Figure 20B). Both APP and GFAP expressed at higher
level in APP23 mice compared to WT mice. APP23 transgenic mice also express
higher level of NICD, indicating activations of Notch signaling.
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Figure 20: Differentiation of HNSCs into astroglial cells in vivo. (A) Representative
fluorescent immunohistochemical images in the hippocampus of WT and APP23 mice
4-6 weeks after HNSCs transplantation. a: WT (8 months old), b: APP23 (8 months old),
and c: Active gliogenesis was detected around plaque-like formations in the
hippocampus of 12 months old APP23 transgenic mice after HNSC-transplantation.
GFAP (green), Abeta stained with 4G8 (red). (B) Western blot analysis of protein
expression of APP, GFAP, and NICD in 8 months old WT and APP23 transgenic mice
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sAPP increases glial differentiation of HNSCs
To investigate effect of APP on HNSC differentiation, we analyzed the cell population of
differentiating HNSCs treated with sAPP for 5 days under serum-free conditions by
double-immunofluorescent staining for GFAP and βIII-tubulin, markers for astrocytes
and neurons respectively (Figure 21A). Treatment with recombinant APP (sAPP) dose
dependently (25, 50, 100 ng/ml) increased the population of GFAP-positive cells from
45% to 83%. Interestingly, a lower dose of sAPP treatment (25 ng/ml) increased both
GFAP and βIII-tubulin-positive cells. However, higher doses of sAPP (50 and 100 ng/ml)
dose-dependently decreased βIII-tubulin-positive cells from 51% to 13% of the total
population of differentiated HNSCs (Figure 21A). These results suggest that sAPP
increases both glial and neuronal differentiations at the lower dose, but in the higher
dose sAPP suppresses neuronal and promotes glial differentiations. The sAPP may be
influencing the cell fate decision of HNSCs because sAPP treatment did not increase
Terminal transferase dUTP nick end labeling (TUNEL) signals, marker for apoptosis, in
the HNSCs culture thus selective death of proneural progenitors in the neurospheres
may be ruled out (data not shown).

Overexpression of APP in vitro reduces neurogenesis of HNSCs
HNSCs were transfected with mammalian expression vectors (pCEP-APP) containing
wild-type APP695 (wtAPP) gene and were differentiated under serum-free
unsupplemented conditions. After 5 days differentiation, HNSCs transfected with wtAPP
differentiated into a significantly higher number of GFAP-positive cells (*: p<0.01, n=3)
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compared to a control, HNSCs transfected with the vector alone (Figure 21B). Neurons
differentiated from HNSCs transfected with wtAPP comprised of less than 7%+SE of the
total number of cells (Figure 21B), whereas the controls showed a 54%+SE neuronal
population (Figure 21A). Furthermore, neurally differentiated cells derived from HNSCs
transfected with wtAPP showed abnormal morphology, reduced length and grossly
misshaped neurite, similar to the neurons derived from NSCs isolated from Down
syndrome patients56. These results indicate that an overdose of the wtAPP gene, which
may produce an increased amount of sAPP fragments, suppress normal neuronal
differentiation and causes gliogenesis rather than neurogenesis of NSCs in vitro.
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Figure 21: Migration and differentiation of HNSCs were altered by treatment of sAPP
and overexpression of APP. (A) Treatment of HNSCs culture with recombinant sAPP for
5 days dose-dependently increased the migration and differentiation of HNSCs under
the serum-free unsupplemented condition (1; control, 2; 25 ng/ml, 3; 50 ng/ml and 4;
100 ng/ml). The cell population of sAPP-treated HNSCs at 5 DIV in the serum-free
differentiation condition was further characterized by double immunofluorescence
staining with GFAP and βIII-tubulin, markers for astrocytes and neurons, respectively.
All nuclei were counterstained with DAPI. At a higher dose of sAPP treatment, many
HNSCs differentiated into glial cells (red). For quantitative population analysis, the
number of GFAP or βIII-tubulin immunopositive cells was counted versus total cell
numbers of DAPI-labeled nuclei. All data values are expressed as mean percentages
(±S.E.M.). One-factor ANOVA followed by post hoc analysis (Student-Newman-Keuls)
was used to demonstrate statistically significant differences between experimental
groups and control groups (*: p<0.01). (B) APP transfection increases the glial
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population of HNSCs in vitro. Double immunofluorescence staining with GFAP (red) and
βIII-tubulin (green). All nuclei are counterstained with DAPI (blue). HNSCs transfected
with mammalian expression vectors containing genes for wild-type APP (wtAPP)
differentiated under serum-free unsupplemented conditions displayed a significantly
reduced level of neural differentiation (a) compared with HNSCs transfected with the
vector alone at 5DIV (b). The abnormal morphology of the processes is shown in
neuronally differentiated HNSCs (green) with wtAPP gene transfection (a).
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sAPP induced GFAP expression in NT-2/D1 cells
To analyze mechanism of the sAPP function to regulate differentiation process of NSCs,
we examined effects of sAPP on differentiation of NT-2/D1 neural progenitor cells.
Expression of GFAP was increased in NT-2/D1 by treatment with recombinant sAPP
with a time- (Figure 22A) and dose-dependent manner (Figure 22B). We also examined
effect of sAPP on GFAP promoter activity using NT-2/D1 cells stably transfected with a
GFAP promoter driven GFP expression vector (pGFAP-GFP-S65T) as a reporter
system. Treatment of NT-2/D1 cells transfected with pGFAP-GFP-S65T with sAPP,
showed a dose-dependent increase of GFP protein expression, indicating that sAPP
induces glial differentiation by activation of GFAP promoter (Figure 22C). For further
investigation, we applied 22C11 antibodies, which can recognize and capture the Nterminal domain of APP, to neutralize the effect of sAPP in glial differentiation of NT2/D1 cells. We observed that treatment with 22C11 effectively antagonized the effect of
sAPP in glial differentiation of NT-2/D1 cells by suppressing GFAP expression levels
(Figure 22D and E). Therefore, these results indicate that sAPP is involved in glial
differentiation of NSCs.
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Figure 22: Induction of GFAP expression in sAPP treated NT-2/D1 cells. (A) Western
blot analysis for measuring GFAP expression. Cells were grown in 100ng/ml of
recombinant sAPP containing media for 0, 15, 30, 45, 60 and 120 min. Expression of βactin was examined as a loading control. (B) Western blot analysis of GFAP expression
which is induced by various concentration (0, 1.5, 5, 15, 50, and 150 ng/ml) of
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recombinant sAPP. Expression of β-actin was examined as a loading control. (C)
Western blot analysis of GFP expression which is transcribed by GFAP promoter.
HEK293 Cells were transfected with pGFAP-GFP-S65T vectors as a reporter system.
To investigate the function of sAPP on GFAP promoter, cells were treated with a variety
of concentration (0, 1.5, 5, 15, and 50 ng/ml) of sAPP. (D) NT-2/D1 cells were treated
with sAPP for 18 hr in the presence of the anti-APP neutralizing Ab (22C11) and
observed the expression changes of GFAP by western blot analysis. Experiments were
repeated at least three times with similar results.
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sAPP induces glial differentiation via Notch signaling pathway
Based on our in vivo findings where higher NICD generation was observed in APP23
mice brain compared to WT, we hypothesized that over expression of sAPP may
stimulate Notch proteolysis and nuclear translocation of NICD resulting in glial
differentiation. To test whether sAPP stimulates the Notch signaling pathway, we
assessed NICD generation in vitro using NT-2/D1 cells treated with sAPP. sAPP
promoted NICD generation as well as increased GFAP protein expression in NT-2/D1
cells (Figure 23A). These results are, consistent with our in vivo results showing that
high dose of sAPP upregulate GFAP expression as well as stimulate an increased
NICD generation (Figure 23B). Next, we investigated both the time- and dosedependent effects of sAPP on the generation NICD (Figure 23B and C). NICD
generation was observed 15 min after treatment with sAPP (100ng/ml). Since NICDs
were generated in an early stage, it suggests that sAPP may stimulate Notch signaling
cascade in a similar manner as the Notch ligands, Jagged and Delta. Upon examination
of the dose dependent effects of sAPP, a gradual increase in NICD generation was
observed in NT-2/D1 cells following treatment with different doses of sAPP (Figure 23B
and C). In contrast, application of 22C11 potently suppressed the generation of NICDs
in a dose dependent manner (Figure 23D). These results provide further evidence that
the notch signaling pathway is stimulated by treatment with sAPP.

105

sAPP stimulates Notch signaling pathway via γ-secretase/nicastrin complex
NICDs are generated by γ-secretase/nicastrin complex under the stimulation of Notch
ligands such as Delta and Jagged1, thus, if sAPP-induced gliogenesis is truly mediated
via Notch signaling pathway, we would expect that the expression of GFAP, Hes1 and
NICD generation would be suppressed by treatment with γ-secretase inhibitors such as,
L-685,458. To further validate whether sAPP stimulates the Notch signaling cascade,
we pretreated various doses (1, 3, and 10 µM) of L-685,458 to NT-2/D1 cells to
suppress γ-secretase activity. Treatment with L-685,458 inhibited both NICD generation
and GFAP expression even in the presence of sAPP (Figure 23E). In addition,
application of L-685,458 potently suppressed the expression of Hes1, a target gene of
Notch (Figure 23F). Taken together, these results strongly suggest that sAPP-induced
glial differentiation is mediated through the Notch signaling pathway.

Recently novel regulatory mechanism in glial differentiation was documented that Notch
and JAK/STAT pathways cross-talk through physical interaction between Hes1 and
JAK2 49. These protein complexes facilitate phosphorylation of STAT3 and maximize
the accessibility of STAT3 to STAT3 binding elements of target promoters including
GFAP. Although sAPP can directly promote phosphorylation of STAT3 through
gp130/IL-6 signaling pathway, somehow, APP-induced Notch signaling activation is also
involved in the phosphorylation status of STAT3 by regulating Hes1 expression. We
thus aimed to examine whether sAPP maximizes glial differentiation by cross-talk
between the Notch and gp130/STAT3 signaling pathways. As shown in Fig. 23E and F,
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Hes1 and GFAP expression were upregulated in NT-2/D1 cells treated with sAPP.
Conversely, treatment of L-685,458 efficiently inhibited Hes1 and GFAP expression by
antagonizing NICD generation. These results suggest that APP-induced Notch signaling
activation also can increase GFAP expression level through gp130/IL-6 related
signaling pathways through cross talk. Thus, to investigate whether APP also enhances
gliogenesis via cross talk with the gp130/IL-6 signaling pathway, phosphorylation of
STAT3-Tyr705 was examined after treatment with APP 45. Treatment of L-685,458 also
suppressed phosphorylation of STAT3-Tyr 705 even in the presence of sAPP (Figure
23G). This is probably caused by downregulation of Hes1 gene expression as reported
previously 49. Although further mechanistic studies are needed, these results suggest
that sAPP potentiates gliogenesis by cross-talk between Notch and gp130/IL-6 signaling
pathways.
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Figure 23: sAPP stimulates Notch signaling pathway during gliogenesis. (A) Treatment
of sAPP (100ng/ml) promoted GFAP expression as well as NICD generation. (B) and
(C) sAPP induced generation of NICD was time- and dose- dependent manner as
indicated above. Generation of NICD was measured by western blot analysis using antiactive Notch Ab (B and C). (D) sAPP induced NICD generation was suppressed by
neutralizing antibody (22C11). (E) and (F) sAPP induced NICD generation was
mediated by stimulation of γ-secretases. L-685,458 (γ-secretase inhibitor) suppressed
expression of GFAP and generation of NICD with dose dependently. Expression of
GFAP and generation of NICD was assessed by western blot analysis using anti-GFAP
Ab and anti-activated Notch Ab, respectively. Furthermore, Hes1 gene expression level
was examined after treatment of sAPP. Then, dose-dependent effect of L-685,458 was
observed by RT-PCR. (G) sAPP enhances cross-talk between Notch and gp130/STAT3
signaling pathway. For detection of phosphorylation of STAT3-Tyr-705,
immunoprecipitation was performed with anti-STAT3 Ab. Then, western blot analysis
was executed using anti-STAT3-Tyr-705 Ab. Expression of β-actin was examined as a
loading control. Experiments were repeated at least three times with similar results.
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Interaction between sAPP and Notch is crucial for glial differentiation
There are two possible mechanisms regarding APP-induced Notch signaling activation.
One is that sAPP may stimulate the Notch signaling cascade by upregulating
expression of Notch receptors or Notch ligands. The other mechanism may be a direct
protein-protein interaction between APP and Notch because several studies reported
that APP can physically interact with Notch. To investigate how sAPP stimulates the
Notch signaling pathway, we first assessed the gene expression levels of Notch related
molecules, such as Delta1, Jagged1, Hes1, hNotch1 and 2, in NT-2/D1 cells after sAPP
treatment (Figure 24A). We observed that the expression of Hes1was drastically
increased following treatment with sAPP, whereas no change in the expression of Notch
ligands (Delta1, Jagged1) and Notch receptors (hNotch1 and 2) were observed. Our
findings indicate that APP-induced Notch signaling activation may not occur by
upregulation of the expression of Notch ligands or Notch receptors. Therefore, to
examine the possibility of the latter mechanism, the physical interaction of APP and
Notch was tested by using immunoprecipitation (Figure 24C). First to identify possible
crucial domain(s) of APP for the physical interaction, we constructed truncated mutants,
APP1-678 and APP1-205, which encode sAPPα (1-678) and N-terminal domain of APP
(1-205), and transfected these mutants, along with an APP expression vector (APP 1695) into NT-2/D1 cells. Interestingly, we found that the N-terminal domain of APP (1205) was sufficient for the physical interaction with Notch. This result is in agreement
with recent reports which have showed physical interactions of APP with Notch. Hence
we confirm here that APP interacts with Notch directly and for the first time we
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demonstrate that a protein-protein interaction is important for sAPP-induced glial
differentiation, mediated by the Notch signaling cascade.
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Figure 24: Physical interaction of APP and Notch is crucial for stimulation of gliogenesis.
(A) sAPP–induced gene expression changes, which are related with Notch signaling
cascade, were assessed by RT-PCR. 100ng/ml of recombinant sAPP protein was
applied to NT-2/D1 cells for 2 hr, then, mRNAs were extracted using Trizol for RT-PCR.
Then, most of Notch related genes were not affected by treatment of sAPP except Hes
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1. Expression of β-actin was examined as a loading control. (B) Schematic diagram of
truncated mutant of APP clones. Several truncated N-terminal domain of APP (1-695, 1678, and 1-205 a.a.) was used for functional analysis. (C) Protein-protein interaction of
APP and Notch was tested by using immunoprecipitation. Proteins were extracted from
NT-2/D1 cells using NP40 lysis buffer. Then, protein complexes were precipitated by
anti-Notch Abs and western blot analysis were performed by using anti-22C11 Abs,
Experiments were repeated at least three times with similar results.
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N-terminal domain of APP is sufficient for induction of glial differentiation
Since the structure of APP harbors a variety of functional domain, sAPP has shown
various physiological functions in vivo as well as in vitro. However, several reports
demonstrate that N-terminal domain of APP has a growth factor like domain because it
contains cystein rich domain and heparin binding site which are involved in proteinprotein interaction. We thus aimed to identify whether N-terminal domain of APP is
sufficient for gliogenesis. For that purpose, we transfected NT-2/D1 cells with three
different APP truncated mutant expression vectors of APP [pCMV-APP695 (1-695),
pCMVIg-APP.1 (1-678), and pCMVIg-APP.2 (1-205)] in. Next, GFAP, Hes1 expression
and NICD generation were examined to investigate the potential function of these
various N-terminal domains of APP in gliogenesis. As shown in Figure 25, N-terminal
domain of APP showed sufficient capability to induce gliogenesis by enhancing GFAP
and Hes1 expression and NICD generation. Several earlier studies have reported that
N-terminal domain of APP promotes proliferation of stem cells because of its growth
factor like structure. Especially, Callie et al. showed that soluble form of APP enhances
proliferation of progenitor cells in adult subventricular zone by acting as a cofactor of
EGF 109. However, we didn’t find any enhanced proliferation in our experimental
conditions, instead we found that treatment of sAPP slightly reduced cell proliferation of
NT-2/D1 cells (data not shown) Therefore, our present study suggests that the Nterminal domain of soluble APP is a potent gliogenic factor to neural precursor cells.
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Figure 25: N-terminal of sAPP is sufficient for glial differentiation. (A) N-terminal domain
of APP induced expression of GFAP as well as generation of NICD. Condition media,
collected from sAPP and their mutants transfected HEK293 cells, were added into NT2/D1 cells. Then, protein extracts were imunnoprecipitated and probed with anti-active
Notch Ab and anti-GFAP Ab, respectively. (B) N-terminal domain of APP enhanced
mRNA expression level of both GFAP and HES1, target gene of NICD. Condition media
were treated into NT-2/D1 cells and total mRNAs were collected using Trizol. Then, RTPCR was performed to amplify target genes using GFAP and HES1 recognizing primer.
Expression of β-actin was examined as a loading control. Experiments were repeated at
least three times with similar results.
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Discussion
APP has been extensively studied in relation to Aβ deposition, which is one of the
hallmarks of the pathophysiology in AD. In the present study, we report a novel
physiological function of sAPP and the mechanisms involving sAPP regulation of cell
fate specification of neural progenitor cells. In general, glial differentiation process is
judged by the expression of GFAP as well as S100β. Although there still remains
unclear whether it is sufficient for identification of gliogenesis, here, we used GFAP as a
marker for the glial differentiation. In our previous studies, we have clarified that sAPP
has a crucial role in altering expression of astrocytic specific markers such as GFAP,
astrocyte-specific glutamate transporter-1(GLT-1)/ excitatory amino acid transporter-2
(EEAT-2), and aspartate transporter-2 (GLAST)/ EEAT-1 expression as well as
morphological changes of neural precursor NT-2/D1 cells 141. Although it has been
reported earlier that sAPP promotes proliferation of NSC both in vitro and in vivo 89, 109,
we observed opposite findings in which treatment of sAPP did not increase the
proliferation of NT-2/D1 cells in our experimental condition (data not shown). Instead we
detected that treatment of sAPP slightly suppressed cell proliferation of NT-2/D1 cells.
Furthermore, sAPP induced GFAP expression in a time- and dose-dependent manner
by stimulating GFAP promoter activity in neural precursor cells. In addition, high levels
of APP induced glial differentiation of HNSCs in vitro as well as in vivo. Therefore, our
data indicates that sAPP is closely associated with the glial differentiation process of
neural precursor cells. To elucidate the molecular mechanisms involved in sAPPinduced gliogenesis, we investigated the specific mechanisms of APP-induced glial
differentiation. In general, bFGF, BMPs, IL-6 cytokine families, and Notch have been the
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most known representatives for the signaling pathway associated with gliogenesis of the
neural stem cells. Recently, He et al. proposed that the Jak/STAT pathway is central to
the gliogenic machinery and postulated a framework for understanding the control of
gliogenesis during development 40. On the other hand, Notch canonical pathway
regulates gliogenesis by either suppressing transactivation of neurogenic bHLH
transcription factors (Mash1 and NeuroD) or cooperating with STAT3 of IL-6 signaling
pathway.

In previous reports, several lines of reports addressed that possible association of
Notch signaling pathway in glial differentiation. In adult DS cortex, the upregulation of
Notch1 and Hes1 expression was observed 170 as well as massive gliogenesis of
HNSCs 56. As discussed before, since AD and DS shows similar characteristics in terms
of the expression level of APP 171, 172 and symptom of the late on-set 123, these results
maybe caused by high concentration of soluble APP. Interestingly, our in vivo study also
suggests that the involvement of Notch signaling pathway in APP-induced glial
differentiation (Figure 20B). When we examined the protein level of APP, GFAP and
NICD in the cortex of both wild type control and APP23 mice using Western blotting,
NICD generation showed higher correlation with GFAP expression level in the cerebral
cortex of APP23 mice compared to WT mice. In accordance with increased APP protein
expression, increases in GFAP protein expression as well as an increase of NICD
generation were observed in the APP23 transgenic mice. Therefore, we examined
Notch signaling pathway as a possible candidate signaling pathway in sAPP-induced
glial differentiation.
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When sAPP was applied to neural precursor cells, it potently generated NICDs with
time- and dose-dependent manner and eventually turned on gene transcription of Hes1,
neuronal repressor. Since these sequential events were usually executed by recruiting
γ-secretase/nicastrin complex under the stimulation of Notch ligands, we examined
whether sAPP can also stimulate Notch signaling pathway similarly with other Notch
ligands such as Deltas or Jaggeds. To determine the specific mechanisms, a γsecretase inhibitor, L-685,458, was used to suppress the function of γ-the
secretase/nicastrin complexL-685,458, inhibited the generation of NICD and induction of
Hes1 gene expression efficiently. Furthermore, the expression of GFAP protein and the
phosphorylation of STAT3 were also diminished by L-685,458. In agreement with our
findings, a recent study reported that the Notch signaling pathway can cross-talk with
the JAK/STAT3 signaling pathway through interaction of Hes1 and JAK2 49. These
complexes enhance the accessibility of STAT3 homodimers to promoter sites and
potentiate gene expression of target genes. These findings suggested that treatment of
sAPP may induce gliogenesis by enhancing GFAP expression via Notch signaling
pathway. On the other hand, sAPP may also suppress glial differentiation by inhibiting
the expression of the neurogenic transcription factors such as NeuroD and Mash1 173.
However, in our experimental conditions, we could detect gene expression of NeuroD
as well as Mash1 in both regular and sAPP treated NT-2/D1 cells. (data not shown)
Thus, this indicates that treatment of sAPP may selectively force cell fate specification
of neural precursors into glia cells by stimulating the Notch signaling cascade.
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Structure of APP 695 largely consists of several characteristic elements. The N-terminal
APP 695 is composed of a signal peptide for the trafficking, a cystein-rich domain
(CRD), a Zinc-binding motif, and acidic sequences 26. The Central APP domain
(CAPPD) consists of a large domain which doesn’t contain cystein residues and a short
linker sequence that harbors α- and β-secretase cleavage sites 26. The C-terminal of
APP harbors a transmembrane region and a cytoplasmic tail. Several lines of evidence
suggested that APP has a structural property similar to a growth factor and ligand.
Thus, we tested here whether the N-terminal domain of APP is enough to induce glial
differentiation of neural stem cells. To elucidate the functional properties of the Nterminal domain of sAPP in glial differentiation, we examined the expression of GFAP
and Hes1, as well as generation of NICDs after treatment with conditioned media which
contained full length APP695, APP1-678, and APP1-205. Treatment of APP and
truncated mutants of APP promoted gene expression of GFAP and Hes1 as well as
NICD generation. These findings suggest that sAPP may function as a ligand for Notch
in neural stem cells treated with APP.

Up to date, it has been in veil how sAPP stimulates these signaling cascades. We thus
hypothesized that there may be two possible ways to stimulate gliogenesis by treatment
with sAPP. First, treatment with sAPP may promote the expression of various ligands or
receptors, associated with Notch receptors, such as Delta and Jagged. The other
possibility is that sAPP may directly interact with Notch molecules to induce signals for
gliogenesis, similar with Notch ligands. If our first hypothesis is correct, treatment of
sAPP would thus induce an increased expression of ligands associated with the Notch
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signaling pathway and sequentially stimulate downstream signaling cascade. However,
our findings indicate that this is not the case since there were no significant changes in
Notch related gene expression except for the Hes1 gene, target of NICD (Fig. 24A). In
the latter case, physical interaction of sAPP with Notch may be the most feasible way to
induce glial differentiation of neural stem cells. To examine our hypothesis, we
performed immunoprecipitation and found that sAPP interacts with Notch. Then, we
found that sAPP physically interacts with Notch (Figure 24C) In support of our findings,
several recent studies have demonstrated protein-protein interaction between APP and
Notch 170, 174, 175.

In conclusion, our present findings address a novel paradigm in the understanding of
glial differentiation mechanisms, which may aid in the development of novel therapeutic
strategies for AD. Current limitation for the clinical use of stem cell therapy in AD is the
low efficacy of neuronal differentiation of transplanted stem cells. Even if stem cells
were transplanted into the brains of AD patient’s brain, these implanted cells would
mainly differentiate into glia due to the higher concentrations of sAPP in vivo. However,
if glial differentiation related signaling pathways are tightly regulated, we may improve
the success rate of stem cell therapy for AD. Therefore, knowledge acquired from this
study may help to understand molecular mechanism of neurodegenerative disease such
as AD and find advanced treatment or prevention methodology for AD.
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GENERAL DISCUSSION
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases
leading to dementia. Since almost 4.5 million patients suffer from AD in America and the
number of patients will be increased to 14 million by year 2050, effective method for
treatment or prevention is urgently necessary 1. Although cytotoxicity of Aβ has been
intensively studied due to its clinical importance, recent studies have shown the
limitation of Aβ theory, such as the irrelevance with phenotypic characteristics of the
amyloid precursor protein (APP) knock-out mice 176. Thus, it tends to lead our concerns
on physiological function of APP in the brain. Despite various physiological functions of
APP have been reported such as neurite outgrowth, cell proliferation, and neural
migration, physiological function of APP is still controversial and remained in veil
because there are little consensus between in vitro and in vivo 26. In the present studies,
we investigated the novel function of APP in stem cell biology, especially, regarding the
differentiation of neural stem cells.

Since serum-free unsupplemented condition does not contain any factors related with
differentiation and growth, NSCs may not be differentiated and survived properly in this
harsh condition. However, previously, we have shown that HNSCs can be differentiated
into neurons, astrocytes, and oligodendrocytes and those cells can be survived up to 3
weeks under the serum free media condition. Thus, our previous results indicate that
some unknown factors, produced endogenously, may affect their own differentiation as
well as survival in the serum-deprived condition. In the present study, we observed the
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elevation of APP expression in apoptotic cells, which has a shrunken morphology,
under the condition of serum-free differentiation of HNSCs. The migration and
differentiation of HNSCs were promoted by the treatment of recombinant sAPP with a
dose-dependent manner. Inversely, when the function of APP was neutralized by Nterminal domain recognizing 22C11 antibody, the effect of APP on HNSCs was
drastically antagonized. Thus, under serum-free differentiation conditions, APP released
from apoptotic cells may serve as a differentiation and/or migration factor for
neighboring HNSCs.

However, a high concentration of sAPP increased the glial cell population of
differentiated HNSCs in vitro. Our results suggest that physiological concentration of
APP enhances the migration and overall differentiation of HNSCs, whereas, higher
concentration of APP, mainly differentiated into glia. Although exact mechanism is still
unclear, several studies showed that elevation of neurogenesis of NSCs was observed
in an early on-set AD patient brain while a massive gliosis is occurred in a late on-set
AD patient brain 177, 178. Based on our results, we might postulate that differentiation of
early on-set AD patient’s NSCs is promoted by the slight elevation of APP expression
level. Since APP level does not reach to the gliogenic threshold, NSC of early stage AD
patient may not be differentiated into glia. Inversely, most of the stem cell population of
AD patient may be differentiated into glia because, as on the disease progressed, the
amount of APP may be increased and will be beyond the gliogenic threshold in the brain.
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Our in vivo study also may support the fact that high dose of APP might cause glial
differentiation since higher expressions of APP and GFAP, typical astrocyte marker,
were observed in APP23 tg mice compared to wild type mice. Although our results do
not directly represent the effect of APP on differentiation of NSCs, at least, it indicates
APP level correlates with GFAP expression in the brain. Consistently, Bahn et al. 56
demonstrated that neurospheres derived from DS patients almost exclusively
differentiated into GFAP positive cells. This may result from an overdose of the APP
gene, since Downs' syndrome patients have inherited three copies of APP that resides
on chromosome 21.

We examined the function of APP in STS-induced glial differentiation of NT-2/D1 cells.
STS has been used as a PKC inhibitor 101as well as an apoptosis inducing reagent 102.
Additionally, several studies showed novel function of STS as a terminal differentiation
inducer in murine embryonic stem cells 104, PC12 pheochromocytoma 105, and C6
glioblastoma 106. Although a molecular mechanism of STS in differentiation remains
unknown, STS-induced differentiation may be associated with an apoptosis mechanism.
Since the elevation of APP is observed in apoptotic cells 80, we postulated increased
APP may influence glial differentiation of NT-2/D1 cells under the apoptotic condition
triggered by STS.

We found that treatment of STS induces apoptosis in NT-2/D1 cells by assessing the
cell viability as well as the DNA fragmentation, a hall mark of apoptosis. Typical
astrocytic morphological changes and typical astrocytic marker such as GFAP,
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GLAST/EAAT1 and GLT1-EAAT2 were appeared in the presence of STS 120,
suggesting that STS induces glial differentiation of NT-2/D1 cells.

We found that treatment of STS gradually increased APP expression as well as
secretion during glial differentiation. Recent studies demonstrated APP has an antiapoptotic function via phosphorylation of myocyte enhancer factor 2 28, 111. Thus, the
increased expression and secretion levels of APP might be a compensatory mechanism
against STS-induced apoptotic condition.

For further studies, gene silencing of APP was performed to examine involvement of
APP in STS-induced glial differentiation. We found that knocking-down expression of
APP significantly reduced GFAP expression in the presence of STS. Although STS may
induce glial differentiation of NT-2/D1 through various signaling mechanisms, this result
suggests that at least APP is associated with the induction of GFAP expression during
STS-induced glial differentiation.

To investigate how STS regulate APP level, we examined APP catabolism/metabolism.
Since APP expression is regulated by phosphorylation of ERK1/2 125 and STS increases
phosphorylation of ERK1/2 116, we postulated that STS may increase APP expression
by promoting ERK1/2 phosphorylation during glial differentiation. We found that MEK1
inhibitor (PD098059), which inhibits phosphorylation of ERK1/2, significantly reduced
expression of APP and GFAP with dose-dependent manner. These results indicate that

124

STS may induce GFAP expression through the upregulation of APP by increasing
ERK1/2 phosphorylation.

To elucidate mechanism relevant to APP-induced glial differentiation, we examined the
potential involvement of IL-6/gp130 and notch signaling pathway 179. Since different
members of the IL-6 cytokine have shown induction of distinct patterns of expression
and phosphorylation status of signaling molecules involved in IL-6/gp130 signaling
pathway 143, treatment of APP may induce distinctive cellular responses. In our
experimental condition, treatment of sAPP activates IL-6/gp130 signaling pathway via a
physical interaction with gp130. Beside the result of immunoprecipitation, treatment of
anti-gp130 antibodies, blocking a ligand binding site of gp130 150, also showed that the
interaction between APP and gp130 is crucial for activation of IL-6/gp130 signaling
since the effect of sAPP was suppressed by anti-gp130 antibodies.

While a rapid phosphorylation of gp130 was induced in an early stage, phosphorylation
of gp130 was quickly reduced back to basal level, presumably, by the internalization of
ligand/IL-6R/gp130 complexes. In previous reports, when gp130 interacts with its
ligands, it is targeted for degradation and gp130 should be synthesized before it
appears in the membrane for preparing next cellular event 145. Thus, treatment of sAPP
significantly may promote the expression of gp130 from 60 min to maintain a certain
amount of gp130 expression in the cell surface as a compensatory mechanism 40.
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Our results have shown that treatment of sAPP promoted the expression of gp130,
CNTF, and JAK1 in early son-set (< 2hr) for glial differentiation. Thus, sAPP may also
stimulate CNTF expression to activate the IL-6/gp130 signaling cascade. The
expression of CNTF, a potent gliogenic factor 179, was increased in an early on-set of
gliogenesis (< 120 min) as well as up to 5 days in the presence of sAPP. However,
since the application of siRNA of CNTF decreased GFAP expression, it reveals that
CNTF may have the crucial function in APP-induced glial differentiation. Though further
studies may be needed, treatment of sAPP may also induce glial differentiation by
upregulating CNTF expression in NT2-D1 cells.

JAK/STAT signaling pathway is an important regulatory system, implicated in GFAP
expression, in glial differentiation 45. Conformational changes of gp130 recruits nonreceptor kinases such as JAKs and activated JAKs phosphorylate STAT3 molecules to
form STAT3 homodimer complexes. Then, STAT3 complexes are translocated into
nucleus to turn on GFAP expression. To examine whether signaling transducing
molecules such as JAKs and STAT3 in APP-induced glial differentiation, we used
siRNA and pharmacological inhibitor for suppressing the function of JAK1/2 or STAT3
molecules. Although treatment of sAPP enhanced phosphorylation of STAT3-p-Tyr705,
siRNA of STAT3, JAK1 and JAK2 inhibitor (AG490) inhibited signal transduction,
caused by APP, and diminished GFAP expression. Therefore, present results suggest
that JAK/STAT molecules are crucial intracellular mediators of the sAPP-induced glial
differentiation of NT-2/D1 cells.
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The notch signaling pathway also has been known as an important glial differentiation
mechanism of NSCs 162. The treatment of sAPP promoted the generation of NICD and
Hes1 gene expression, suggesting the activation of notch signaling in NT-2/D1 cells.
However, since treatment of γ-secretase inhibitors (L-685,458) suppressed NICD
generation, Hes1 expression, and GFAP expression in the presence of sAPP, our
results indicate that sAPP can induce glial differentiation of neural progenitor cells via
notch signaling pathway.

We examined mechanisms associated with APP-induced notch signaling activation to
elucidate how sAPP stimulate notch signaling pathway. One possibility is that sAPP
may stimulate notch signaling cascade by increasing the expression of notch receptors
and/or ligands such as Delta and Jagged. However, this possibility should be ruled out
because mRNA expression level of Notch1, 2, Jagged, and Delta was not changed by
treatment of sAPP. Instead, we found that APP can stimulate notch signaling cascade
by physical interaction with notch receptors using immunoprecipitation. Several recent
studies also have demonstrated a protein-protein interaction between APP and Notch in
support of our findings 170, 174, 175. Interestingly, N-terminal domain of APP (1-205) was
enough to interact with Notch and promotes NICD generation as well as Hes1
expression. Also, APP (1-205) domain was sufficient to induce GFAP expression level
in both protein and mRNA as well. It may be the reason that treatment of N-terminal
recognizing antibodies (22C11) suppresses NICD generation as well as GFAP
expression since a ligand/receptor binding is blocked by 22C11. Therefore, protein-
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protein interaction of APP with gp130 and notch receptor may be the crucial for the
induction of glial differentiation.

Previously, Kamakura et al. demonstrated IL-6 signaling and notch can cross-talk and
have a synergistic effect through interaction of Hes1 and JAK2 49. These complexes
enhance the accessibility of STAT3 homodimers to promoter sites and potentiate the
expression of target genes (ex, GFAP). Our results also indicate that treatment of γsecretase inhibitor suppressed GFAP expression as well as STAT3 phosphorylation via
cross-talking between IL-6/gp130 and notch signaling pathway. However, APP-induced
glial differentiation may be not modulated by a synergistic way but induced by activation
of both IL-6 and notch signaling for the glial differentiation. If APP-induced glial
differentiation is occurred synergistically, although one signaling cascade (IL-6/gp130 or
notch) is blocked by antibodies, siRNAs, or chemical inhibitors, we could observe
certain level of GFAP expression, higher than control, because APP can still activate
the other signaling pathway. However, when one signaling cascade is suppressed,
overall GFAP expression level was decreased almost back to basal level. Therefore,
our findings indicate that the activation of both two signaling cascade may be necessary
for APP-induced glial differentiation.
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Figure 26: Schematic diagram of sAPP-induced glial differentiation mechanism.
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Although the rate of neurogenesis of endogenous NSCs in the AD patient brain is
slightly promoted in their early on-set 177, 178, in the long run, pathologically-altered APP
metabolism in AD or DS may cause a defect in neurogenesis and significantly destroy
normal brain functions due to massive glial differentiation of endogenous NSCs. A
gliogenic APP function could also prevent successful stem cell therapy for AD using
NSC by influencing the differentiation of the transplanted cells into glial cells rather than
into neurons. Thus, in order to use stem cell transplantation as a potential strategic
intervention therapy for AD or DC, regulation of environmental APP levels and/or
modifications of the APP signal pathways within the cells may need to be developed.
Therefore, regulation of APP level could be a promising strategy to increase
neurogenesis in AD brain.
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